

Date of Preparation: 8/1//21

Signature

Jeffrey W. Taub, M.D.
Curriculum Vitae

OFFICE ADDRESS:

Children's Hospital of Michigan
3901 Beaubien Boulevard
Detroit, Michigan 48201

Telephone:

313-745-5515

Fax: 313-745-5237

EDUCATION:

Vincent Massey, Centennial High School
Windsor, Ontario, Canada

Faculty of Sciences
The University of Western Ontario
London, Ontario, Canada
(completed two years of Honors Chemistry B.S.)

Faculty of Medicine
The University of Western Ontario
London, Ontario, Canada
(M.D. Degree; June 5, 1987)

POSTGRADUATE TRAINING:

06/1987-06/1988	Transitional Internship Victoria Hospital, London, Ontario, Canada
07/1988-06/1991	Pediatric Residency Children's Hospital of Michigan, Detroit, Michigan
07/1991-06/1994	Fellowship in Pediatric Hematology/Oncology Children's Hospital of Michigan, Detroit, Michigan

FACULTY APPOINTMENTS:

07/01/94 - 08/19/00	Assistant Professor of Pediatrics Wayne State University School of Medicine, Detroit, MI
08/20/00 – 06/30/05	Associate Professor of Pediatrics Wayne State University School of Medicine, Detroit, MI
07/01/05 – 8/18/09	Associate Professor of Pediatrics (Tenure) Wayne State University School of Medicine, Detroit, MI
8/19/09-present	Professor of Pediatrics (Tenure) Wayne State University School of Medicine, Detroit, MI
6/1/2015-present	Professor of Oncology Wayne State University School of Medicine, Detroit, MI

7/1/201-present Clinical Professor of Pediatrics
Central Michigan University

HONORS/AWARDS:

- 1981 Province of Ontario Scholar, 1981; Reach for the Top University Scholarship
- 1981 University of Western Ontario - four year admission scholarship
- 1991 Recipient of Sanford N. Cohen Award for outstanding performance during residency. Children's Hospital of Michigan, 1988-1991.
- 1994 Young Investigator Award, American Society of Clinical Oncology.
- 1995 Outstanding Poster Award, at the 86th Annual Meeting of the American Association for Cancer Research (March 18-22, 1995).
- 2000, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021 Listed in Hour Detroit Magazine, "Top Doctors".
- 2002 - 2007 Scholar in Clinical Research, Leukemia and Lymphoma Society
- 9/2005- Ring Screw Textron Endowed Chair in Pediatric Cancer Research-Children's Hospital of Michigan/Wayne State University School of Medicine
- 2008 Wayne State University Faculty Research Excellence Award
- 2010 Dinner Honoree, 29th Annual Evening of Hope, Leukemia Research Life, Inc.
- 2010 Children's Hospital of Michigan Celebration of Life Award
- 2010 Children's Hospital of Michigan Teacher of the Year Award (Professor)
- 2015 Physician Difference Maker Award, Children's Hospital of Michigan (December)
- 2018 Crain's Detroit Business Newspaper Health Care Hero

SERVICE:

Professional:

Children's Oncology Group

Study Chair: AAML 0431 The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years. A Group-Wide Phase III Study. Enrollment: 205 patients

Vice Study Chair: AAML08B1 Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)

Study Committee member: AAML0523 A Phase II Study of CLOLAR (Clofarabine, IND# 63,641) in Combination with Cytarabine in Pediatric Patients with Refractory/Relapsed Leukemia

Study Committee member: AAML1531 "Risk Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome".

TEACHING:

1. Years at Wayne State University: 27

Resident/Fellows: Pediatric House Officers: Ward/bedside teaching on a daily basis while primary attending on 6 West and the Hematology/Oncology inpatient consult service

f. Doctoral Student Dissertation committee (Wayne State University):

Yijun Deng (2005-2008) Study of cellular folate transport by plasma membrane transporters and mitochondrial membrane transporter.

Amanda Larson Gedman (2007-2010) Study of NOTCH1 receptor and HES1 in T-cell acute lymphoblastic leukemia.

Sita Desmoulin (2009-2012) The human proton coupled folate transporter as a novel approach for therapeutic targeting of solid tumors.

John Caldwell (2011-2014) Chemotherapy resistance in Down syndrome pediatric acute myeloid leukemia. [MD/PHD thesis advisor]

Dan Luedtke (2017-2019) Strategies to enhance the anti-leukemic activity of venetoclax (ABT-199) in AML through targeting of MCL-1.

g. Other

Organizer/host of the Children's Hematology Alliance of Michigan (CHAM) 3rd Annual Educational Symposium held at CHM, 9/11/15.

Mentorship:

Anjali Sharathkumar, M.D. (Pediatric Resident Children's Hospital of Michigan)

i) Recipient of American Academy of Pediatrics Research Grant: Does Differential Gene Expression Account for Biological Differences Between the Transient Myeloproliferative Disorder (TMD) and Megakaryocytic Leukemia (AMKL) in Down Syndrome Children. 2004-2005, \$2000.

ii) Outcome of Children with Hyperdiploid Acute Lymphoblastic Leukemia: Is There a Predisposition for Extramedullary Relapse.

Recipient of the: i) Sheldon Brenner Pediatric Resident Research Award, Children's Hospital of Michigan (June 2004); ii) Clinical Study Award at the Resident Project Forum at the 55th Annual Meeting of the Michigan Chapter of the American Academy of Pediatrics, Mackinac Island (Oct. 1, 2004). Presented at The Annual Meeting of the American Society of Hematology 2004. [Publication #48; Abstract #53]

Postdoctoral Fellow Mentorship:

1) Xi Huang, M.D., Ph.D. (1998-2000) Currently: Assistant Professor, Department of Anatomy, Wayne State University School of Medicine.

2) Yubin Ge, Ph.D. (2000-2005) Currently: Associate Professor (Tenure), Karmanos Cancer Institute and Department of Pediatrics, Wayne State University School of Medicine

3) Ana Xavier, M.D. (2007-2009) Pediatric Hematology/Oncology Fellow, Children's Hospital of Michigan. Recipient of a grant from the St. Baldrick's Foundation titled "The Role of GATA1s in Down Syndrome AML Biology and Therapy". 7/2008-6/2010. \$100,000. [Publications: # 53, 58; Abstracts # 68, 71]

4)Mara Rubenstein, M.D. (2011-2013) Pediatric Hematology/Oncology Fellow, Children's Hospital of Michigan. Genetic Factors Linked to the Presenting White Blood Cell Count in Childhood Acute Lymphoblastic Leukemia. [Publication #108] Recipient of the 2013 Children's Hospital of Michigan Wolf Zuelzer Pediatric Fellow Research Award.

5)Kelley K. Hutchins, D.O. (2014-2017) Pediatric Hematology/Oncology Fellow, Children's Hospital of Michigan. Clinical trial enrollment and follow-up visit rates among survivors of childhood cancer [Publication #120]

6)Tristan Knight, M.D. (2016-2019) Pediatric Hematology/Oncology Fellow, Children's Hospital of Michigan. Combination of CUDC-907 and Gilteritinib Shows Synergistic Anti-leukemic activity against FLT3-ITD AML. Recipient of the 2018 Children's Hospital of Michigan Wolf Zuelzer fellowship research award.

7)Margaret Shatara, M.D. (2016-2019) Pediatric Hematology/Oncology Fellow, Children's Hospital of Michigan. Inhibition of ATR Potentiates Acute Myeloid Leukemia Cells to the RNA Polymerase I Transcription Inhibitor CX-5461. Recipient of the 2019 Children's Hospital of Michigan Wolf Zuelzer fellowship research award.

8)Eman Al-Antary, MD (2019-2022) Pediatric Hematology/Oncology Fellow. Children's Hospital of Michigan. Novel Therapy for Cytarabine Resistant AML Utilizing the Combination of AZD5991 and ONC213. Funded by the Children's Hospital of Michigan Foundation \$30,000.

9)Avante Gupte, MD (2019-2022) Pediatric Hematology/Oncology Fellow. Children's Hospital of Michigan. Co-targeting Bcl-2 and CDK9 to combat cytarabine resistance in AML. Funded by the Children's Hospital of Michigan Foundation \$11,000.

GRANTS, CONTRACTS, AND OTHER FUNDING:

Extramural

- 1) The mechanisms of chemotherapy sensitivity in Down Syndrome. **JW Taub, Principal Investigator**. Young Investigator Award, American Society of Clinical Oncology, July 1, 1994 - June 30, 1995, \$ 25,000.
- 2) The molecular basis of cytarabine sensitivity of Down Syndrome children. **JW Taub, Principal Investigator**. Children's Cancer Research Fund; 8/95-7/96, \$ 29,649.
- 3) "Correlates of Methotrexate Resistance in Childhood Acute Lymphocytic Leukemia". L. Matherly, PI, **JW Taub, Co-Investigator**. American Cancer Society. \$ 240,000. 01/01/96 - 12/31/97.
- 4) "The Relationship of Methotrexate Therapy and Long-Term Neuropsychological Effects in Childhood Acute Lymphoblastic Leukemia Survivors." **JW Taub, Principal Investigator** \$ 23,163. Children's Leukemia Foundation of Michigan. 07/01/97 - 06/30/99.
- 5) "The Molecular Basis of Chemotherapy Sensitivity of Down Syndrome Children with Leukemia." **JW Taub, Principal Investigator** \$ 400,000. The Leukemia and Lymphoma Society (*formerly, Leukemia Society of America*). 09/01/97 - 08/31/2001.

- 6) "The Correlation of Dihydrofolate Reductase (DHFR) Levels in Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL) with Ethnic Background and Treatment Outcome." **JW Taub, Principal Investigator** \$ 32,144. Pediatric Oncology Group. 1997-1998.
- 7) Molecular Correlates of Methotrexate in Childhood ALL." L. Matherly, P.I.; **JW Taub, Co-Investigator**. National Cancer Institute, # RO1 CA76641. 01/01/98 - 12/31/2002, \$ 782,945. (direct costs). Renewed: 1/1/03-12/31/08.
- 8) "Cystathionine- β -Synthase and Ara-C Therapy for Leukemia." **JW Taub, Principal Investigator** \$ 18,000. Pediatric Oncology Group, 1/01/2000 -12/31/2000.
- 9) "Cystathionine- β -Synthase and Ara-C Therapy for Leukemia." **JW Taub, Principal Investigator**, National Cancer Institute (NCI), RO1 CA092308; 07/01/2001 - 06/30/2007; \$1,173,375. (Total costs).
- 10) "Friends Like Me" Program. (Pediatric Cancer Survivors Program at Children's Hospital of Michigan, Detroit, MI), The Jewish Fund (Detroit, MI). **JW Taub, Co-Principal Investigator**. 2001-2003, \$ 150,000. (\$ 50,000/yr).
- 11) "Down Syndrome, Leukemia and Cystathionine-beta-Synthase." **JW Taub. Scholar in Clinical Research**, Leukemia and Lymphoma Society. 7/1/02-6/30/07. \$ 500,000 (salary support).
- 12) St. Jude Children's Research Hospital 7/01/03-6/30/08. Treatment of Patients with newly diagnosed Acute myeloid leukemia or myelodysplasia (AML02) a collaborative trial of St. Jude Children's research hospital, Stanford University Medical Center, Cook Children's Medical Center and Wayne State University. Reimbursement per patient enrollment.
- 13) Children's Oncology Group Subcontract No. 13533, **Chair Award to JW Taub**. \$13,212/year (total costs), National Childhood Cancer Foundation U10 CA98543-02 3/1/04-2/28/11.
- 14) "Differences in Etiology of Acute Lymphoblastic Leukemia Between Caucasian and African American Children." **JW Taub, Principal Investigator**, The Gerber Foundation. \$384,668. 7/1/2006-6/30/2009. The Gerber Foundation.
- 15) "Molecular and Pharmacologic Correlates of Acute Myeloid Leukemia in Down Syndrome." **JW Taub, Principal Investigator**. National Cancer Institute (NCI), R01 CA120772; 07/06/2007-4/30/2014; \$2,189,783 (total costs).
- 16) "Resources, Parent-Child Communication and Adjustment to Pediatric Cancer." L. Penner (P.I.) National Cancer Institute (NCI), RO1 CA138981 (Louis Penner, P.I.), **JW Taub, Co-investigator**. August 2009-July 2014, Direct Costs: \$2,477,803.
- 17) "Targeting Bcl-2 for the Treatment of Acute Myeloid Leukemia." **JW Taub, Principal Investigator** Hyundai Scholar Senior Researcher Award. December 2015-November 2018, \$250,000.
- 18) "Psycho-social resources for pediatric cancer patients." **JW Taub, Principal Investigator**. CureSearch. 11/1/2015-10/31/2016, \$19,610.

Leukemia, Research, Life, Inc (Detroit, MI).

- 19) "Cytosine Arabinoside and Gemcitabine Therapy for Pediatric Malignancies." **JW Taub, Principal Investigator.** \$ 100,000. 01/01/2000 - 12/31/2001.
- 20) "A NOD/SCID Mouse Model for Childhood Leukemias." L. Matherly, P.I.; **JW Taub Co-Investigator.** \$50,000. 01/01/02-12/31/03.
- 21) "The Role of AML1 in Chemotherapy Sensitivity in Pediatric Acute Myeloid Leukemia." **JW Taub, Co-investigator.** \$50,000. 2007-2008.
- 22) "Notch1 Mutations and the Etiology of Childhood T-cell Acute Lymphoblastic Leukemia." **JW Taub, Co-Principal Investigator,** \$50,000. 2007-2008.
- 23) "NOTCH1 Signaling and Chemotherapy of T-Cell Acute Lymphoblastic Leukemia in Children Leukemia." **JW Taub, Co-investigator.** \$50,000. 2008-2009
- 24) "Enhancement of Chemotherapy Activity Against Childhood Acute Myeloid Leukemia Utilizing Valproic Acid." **JW Taub, Co-investigator.** \$50,000. 2008-2009
- 25) "Combination Therapy of Clofarabine Against Childhood Leukemia." **JW Taub and Y Ge, Co-Principal Investigators.** \$50,000. 2008-2009
- 26) "Exploiting the PI3K/AKT/mTOR Pathways for the Treatment of T-Cell Acute Lymphoblastic Leukemia in Children." **JW Taub, Co-investigator.** \$50,000. 2008-2009

Children's Hospital of Michigan Foundation

- 27) "The Role of Environmental Exposures and the Development of TEL-AML1 Leukemia in Zebrafish Model" **JW Taub and R. Thummel, Co-Principal Investigators.** Children's Hospital of Michigan Foundation/ Kids Without Cancer, Inc.; 1/1/15-12/31/15, \$50,000
- 28) "Development of New Therapeutic Agents for Pediatric Acute Myeloid Leukemia" **JW Taub and Y Ge, Co-Principal Investigators.** Children's Hospital of Michigan Foundation. 1/1/15-12/31/15, \$45,000.
- 29) "Development of Novel Therapies for Children with Acute Myeloid Leukemia" **JW Taub and Y Ge, Co-Principal Investigators.** Children's Hospital of Michigan Foundation. 1/1/15-12/31/15, \$50,000.
- 30) "Kids Without Cancer Zebrafish Initiative" R. Thummel (P.I.), **JW Taub, Co-investigator.** Children's Hospital of Michigan/Kids Without Cancer, Inc.; 12/1/16-11/30/20, \$319,625.
- 31) Novel Hybrid Drugs for the Treatment of AML and Neuroblastoma. **JW Taub and Y Ge, Co-Principal Investigators.** Children's Hospital of Michigan/LaFontaine Family Foundation. \$94,000.
- 32) Novel Immunotherapy for the Treatment of Acute Myeloid Leukemia. **JW Taub and Y Ge, Co-Principal Investigators.** Children's Hospital of Michigan Foundation/LaFontaine Family Foundation. \$78,000.

Intramural

1. Research Stimulation Support, 144981-95-96. \$ 10,000. WSU, Research & Sponsored Programs. **JW Taub**.
2. "The Molecular Basis of Chemotherapy Sensitivity of Down Syndrome Children with Leukemia". **JW Taub, Principal Investigator**. \$ 25,000. CHM Intramural Grant Fund. 07/01/97 - 06/30/98.
3. "The Identification of Leukemic Genetic Markers in Blood Spots of Guthrie Newborn Screening Cards from Individuals Previously Diagnosed with Childhood Acute Lymphoblastic Leukemia." **JW Taub, Principal Investigator**. \$ 25,000. CHM Intramural Grant. 01/01/99 - 12/31/99.
4. "Differences in Etiology of Acute Lymphoblastic Leukemia between Caucasian and African American Children." **JW Taub, Principal Investigator**. \$200,000. WSU Research Enhancement Program 5/01/04-4/30/06.

PEER-REVIEWED PUBLICATIONS:

1. Taub JW, Warrier I, Holtkamp C, Beardlsey DS, Lusher JM. Characterization of autoantibodies against the platelet glycoprotein antigens IIb/IIIa in childhood immune thrombocytopenia purpura. American Journal of Hematology 48:104-107, 1995.
2. Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, Gimotty P, Buck S, Wright JE, Rosowsky A. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85:500-509, 1995.
3. Taub JW, Matherly LH, Stout M, Buck SA, Gurney JG, Ravindranath Y. Enhanced metabolism of 1- β -D-arabinofuranosylcytosine in Down Syndrome cells: a contributing factor to the superior event-free survival of Down Syndrome children with acute myeloid leukemia. Blood 87:3395-3403, 1996.
4. Taub JW, and Ravindranath Y. Treatment of childhood acute myelogenous leukemia. Bailliere's Clinical Haematology 9:129-146, 1996.
5. Matherly LH, Taub JW: Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leukemia and Lymphoma 21:359-368, 1996.
6. Matherly LH, Taub JW, Ekizian R, Wong SC, Buck S, Simpson P, Amylon M, Pullen J, Camitta B, and Ravindranath Y. Increased frequency of heterogeneous expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphocytic leukemia in children. Blood 90:578-589, 1997.
7. Jolivet J, Faire MP, Ouimet M, Pinard MF, Wong SC, Taub JW, Matherly LH. Confocal microscopic visualization of antifolate uptake by the reduced folate carrier in human leukemic cells. British Journal of Cancer 76:734-738, 1997.
8. Savasan S, Taub JW, Ravindranath Y. Down Syndrome and leukemia - a perspective overview. Turkish Journal of Pediatrics 39:519-531, 1997.
9. Taub JW, Stout ML, Buck SA, Huang X, Vega RA, Becton DL, Ravindranath Y. Myeloblasts from Down Syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. Leukemia 11:1594-1595, 1997.

10. Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, Pullen J, Ravindranath Y, Matherly LH. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clinical Cancer Research 4:2169-2177, 1998.
11. Taub JW. Factors in improved survival from pediatric cancer. Drugs 56:757-765, 1998.
12. Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, Becton DL, Chang MN, Weinstein HJ, Ravindranath Y. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down Syndrome and non-Down Syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 94:1393-1400, 1999.
13. Matherly LH, Taub JW: Molecular and cellular correlates of Methotrexate response in childhood acute lymphoblastic leukemia. Leukemia and Lymphoma 35:1-20, 1999.
14. Ravindranath Y, Taub JW. Down syndrome and acute myeloid leukemia. Lessons learned from experience with high-dose Ara-C containing regimens. Advances in Experimental Medicine and Biology 457:409-414, 1999.
15. Savasan S, Taub JW. Down Syndrome and Leukemia: What have we learned? Pediatric Pathology & Molecular Medicine 19:269-281, 2000.
16. Taub JW, Huang X, Ge Y, Dutcher JA, Stout ML, Mohamad RM, Ravindranath Y, Matherly LH. Cystathionine- β -synthase cDNA transfection alters the sensitivity and metabolism of cytosine arabinoside in CCRF-CEM leukemia cells in vitro and in vivo: a model of Down Syndrome in leukemia. Cancer Research 60:6421-6426, 2000.
17. Shah SJ, Taub JW, Witt TL, Pollock BH, Bing B-C, Moore DS, Amylon M, Pullen J, Ravindranath Y, Matherly LH. Relationship of p15 and p16 gene alternations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukemia. British Journal of Haematology 113:746-756, 2001.
18. Taub JW. The relationship of Chromosome 21 and acute leukemia in Down Syndrome. J Pediatric Hematology Oncology 23:175-178, 2001.
19. Ge Y, Konrad MA, Matherly LH, Taub JW. Transcriptional regulation of the human cystathionine- β -synthase -1b promoter: synergistic transactivation by transcription factors NF-Y and Sp1 /Sp3. Biochemical Journal 357:97-105, 2001.
20. Savasan S, Taub JW, Buck S, Botterill M, Furlan M, Ravindranath Y. Congenital microangiopathic hemolytic anemia and thrombocytopenia with unusually large von Willebrand factor multimers and von Willebrand factor-clearing protease. Journal of Pediatric Hematology Oncology 23:364-367, 2001.
21. Whetstine JR, Gifford A, Witt T, Liu XY, Flatley R, Norris M, Haber M, Taub JW, Ravindranath Y, Matherly LH. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high frequency G $\rightarrow$ A variant at position 80 and transport properties of the His²⁷ and Arg²⁷ carriers. Clin Cancer Res 7:3416-3422, 2001.
22. Ge Y, Matherly LH, Taub JW. Transcriptional regulation of cell-specific expression of the human cystathionine- β -synthase gene by differential binding of SP1/SP3 to the -1B promoter. J Biol Chem 276:43570-43579, 2001.

23. Taub JW and Ravindranath Y. Down syndrome and the transient myeloproliferative disorder – why is it transient? J Ped Hem-Onc 24:6-8, 2002.
24. Taub JW, Matherly LH, Ravindranath Y, Kaspers GJL, Rots MG, van Zantwijk CH. Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. Leukemia 16:764-765, 2002.
25. Ge Y, Jensen T, James SJ, Weinstein HJ, Becton DL, Massey GV, Ravindranath Y, Matherly LH, Taub JW. High frequency of the 844 ins 68 cystathionine- β -synthase gene variant in Down Syndrome children with acute myeloid leukemia. Leukemia 16:2339-2241, 2002.
26. Taub JW, Konrad MA, Ge Y, Naber JM, Scott JS, Matherly LH, Ravindranath Y. High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood 99:2992-2996, 2002.
27. Ge Y, Jensen TL, Matherly LH, Taub JW. Synergistic regulation of human cystathionine- β -synthase -1B promoter by transcription factors NF- κ B isoforms and Sp1. Biochimica et Biophysica Acta 1579:73-80, 2002.
28. Gifford AJ, Haber M, Witt TJ, Whetstone JR, Taub JW, Matherly LH, Norris MD. Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells. Leukemia 16:2379-2387, 2002.
29. Ge Y, Jensen TL, Matherly LH, Taub JW. Transcriptional regulation of the cystathionine- β -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Blood 101: 1551-1557, 2003.
30. Ge Y, Jensen TL, Matherly LH, Taub JW. Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity. Journal of Biological Chemistry 278:49901-49910, 2003.
31. Taub JW, Ge Y. The prenatal origin of childhood acute lymphoblastic leukemia-review. Leukemia & Lymphoma 45:19-25, 2004.
32. Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Research 64: 728-735, 2004.
33. Flatley RM, Payton SG, Taub JW, Matherly LM. Primary acute lymphoblastic leukemia cells use a novel promoter and 5'non-coding exon for the human reduced folate carrier that encodes a modified carrier translated from an upstream translational start. Clinical Cancer Research 10:5111-5122, 2004.
34. Taub JW, Mundschaug G, Ge Y, Poulik J, Qureshi F, Jensen TL, Matherly LH, James J, Weschler J, Crispino JD. Prenatal origin of GATA1 mutations may be an initiating step in the development of leukemia in Down syndrome. Blood 104:1588-1589, 2004.
35. Taub JW, Ge Y. Down Syndrome, drug metabolism and chromosome 21. Pediatric Blood and Cancer. 44:33-39, 2005.

36. Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, Thomas RL, Ravindranath Y, Matherly LH, Taub JW. Gata1, cytidine deaminase and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. Journal of the National Cancer Institute 97:226-231, 2005.
37. Ge Y, Jensen TL, Tatman D, Stout ML, Buck SA, Ravindranath Y, Matherly LH, Taub JW. Role of USF1 in the differential expression of the human deoxycytidine kinase gene in acute myeloid leukemia. Leukemia 19: 677-679, 2005.
38. Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G., Becton DL, Weinstein HJ, Ravindranath Y, Matherly LH, Taub JW. Differential gene expression, GATA1 target genes and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 107: 1570-1581, 2006.
39. Liu M, Ge Y, Payton SG, Aboukameel A, Buck S, Flatley RM, Haska C, Mohammad R, Taub JW, Matherly LH. Transcriptional regulation of the human reduced folate carrier in childhood acute lymphoblastic leukemia cells. Clinical Cancer Research 15: 608-616, 2006.
40. Yang LV, Wan J, Ge Y, Fu Z, Kim SY, Fijiwara Y, Taub JW, Matherly LH, James Eliason J, Li L. The GATA site-dependent Hemogen Promoter Is Transcriptionally Regulated by GATA1 in Hematopoietic and Leukemia Cells. Leukemia 20: 417-425, 2006.
41. Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW, Ravindranath Y, Dahl G, Weinstein HJ. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): A Children's Oncology Group (COG) Study POG-9481. Blood 107: 4606-4613, 2006.
42. Muntean AG, Yubin Ge Y, Taub JW, Crispino JD. Transcription Factor GATA-1 and Down Syndrome Leukemogenesis. Leukemia and Lymphoma 47: 986-997, 2006.
43. Cushing T, Clericuzio CL, Wilson CS, Taub JW, Ge Y, Winter SS. Risk for leukemia in non-Down syndrome infants with transient myeloproliferative disorder. Journal of Pediatrics 148: 687-689, 2006.
44. Cline RJ, Harper FW, Penner LA, Peterson AM, Taub JW, Albrecht TL. Parent communication and child pain and distress during painful pediatric cancer treatments. Social Science & Medicine 63: 883-898, 2006.
45. Peterson AM, Cline RJW, Foster TS, Jones EM, Penner LA, Parrott RL, Keller CM, Naughton MC, Taub JW, Ruckdeschel JC, Albrecht TL. Parents' interpersonal distance and touch behavior and child pain and distress during painful pediatric oncology procedures. Journal of Nonverbal Behavior 31: 79-97, 2007.
46. Ge Y, Haska CL, LaFiura K, Devidas M, Linda SB, Liu M, Thomas R, Taub JW, Matherly LH. Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Clinical Cancer Research 13: 451-457, 2007.

47. LaFiura KM, Bielawski DM, Posecion NC, Ostrea EM, Matherly LH, Taub JW, Ge Y. Association between prenatal pesticide exposures and the generation of leukemia-associated t(8;21). Pediatric, Blood and Cancer 49:624-628, 2007.
48. Sharathkumar A, Deborah DeCamillo D, Bhambhani K, Cushing B, Thomas R, Mohamed AN, Ravindranath Y, Taub JW. Children with Hyperdiploid but not Triple Trisomy (+4,+10,+17) Acute Lymphoblastic Leukemia have an Increased Incidence of Extramedullary Relapse on Current Therapies: A Single Institution Experience. American Journal of Hematology 83: 34-40. 2008.
49. O'Brien MM, Taub JW, Chang M, Stine K, Raimondi S, Becton D, Ravindranath Y, Dahl GV. Cardiomyopathy in Children with Down Syndrome Treated for Acute Myeloid Leukemia: A Report from the Children's Oncology Group Study POG 9421. Journal of Clinical Oncology 26: 414-420, 2008.
50. Alcasabas P, Ravindranath Y, Goyette G, Haller A, del Rosario L, Lesaca M, Darga L, Ostrea E, Taub JW, Everson R. 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphisms and the risk of acute lymphoblastic leukemia (ALL) in Filipino children. Pediatric, Blood and Cancer 51: 178-182, 2008.
51. Ge Y, LaFiura KM, Dombkowski AA, Chen Q, Payton SG, Buck SA, Salagrama S, Diakiw AE, Matherly LH, Taub JW. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia 22:521-529, 2008.
52. LaFiura KM, Edwards H, Taub JW, Matherly LH, Fontana JA, Mohamed AN, Ravindranath Y, Ge Y. Identification and characterization of novel AML-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: A report from the Children's Oncology Group. Oncogene 27: 4933-4942, 2008.
53. Xavier AC, Ge Y, Taub JW. Down Syndrome and Leukemia: A Model of Leukemogenesis and Cure. International Journal of Disability and Human Development 7: 385-395, 2008.
54. Gruhn B, Taub JW, Ge Y, Beck JF, Zell R, Häfer R, Hermann FH, Debatin K-M, Steinbach D. Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy. Leukemia 22: 1692-1697, 2008.
55. Pranzatelli MR, Tate ED, Travelstead AL, Baumgardner CA, Gowda NV, Halthore SN, Kerstan P, Kossak BD, Mitchell WG, Taub JW. Insights on Chronic-Relapsing Opsoclonus-Myoclonus from a Pilot Study of Mycophenolate Mofetil. Journal of Child Neurology 24:316-322, 2009.
56. Penner LA, Cline RJW, Albrecht TL, Harpter FWK, Peterson AM, Taub JW, Ruckdeschel JC. Parents' emphatic responses and pain and distress in pediatric patients. Basic and Applied Social Psychology 30: 102-113, 2008.
57. Gedman AL, Chen Q, Desmoulin SK, Ge Y, LaFiura K, Christina L. Haska CL, Cherian C, Devidas M, Linda SB, Taub JW, Matherly LH. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T- cell acute lymphoblastic leukemia: A report from the Children's Oncology Group. Leukemia 24:1417-1425, 2009.
58. Xavier AC, Ge Y, Taub JW. Down syndrome and malignancies : A unique clinical

- relationship. Journal of Molecular Diagnostics 11:371-380, 2009.
59. Cabelof DC, Patel HV, Chen Q, van Remmen H, Matherly LH, Ge Y, Taub JW. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down Syndrome. Blood 114:2753-2763, 2009.
60. Edwards H, Xie C, LaFiura KM, Dombkowski A, Buck S, Boerner J, Taub JW, Matherly LH, Ge Y. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 114:2744-2752, 2009.
61. Xavier AC, Ge Y, Taub JW. Unique clinical and biological features of leukemia in Down syndrome children. Expert Reviews in Hematology 3:175-186, 2010.
62. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Leung W, Pui CH, Campana D. Minimal Residual Disease-Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial. Lancet Oncology 11: 543-552, 2010.
63. Xavier AC, Taub JW. Acute leukemia in children with Down syndrome. Haematologica 95: 1043-1045, 2010.
64. Xie C, Edwards H, Xu X, Zhous H, Buck SA, Stout ML, Yu Q, Rubnitz JE, Matherly LH, Taub JW, Ge Y. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clinical Cancer Research 16:5499-5510, 2010.
65. Gamis AS, Alonzo TA, Hilden JM, Gerbing RB, Sorrell AD, Kumar M, Loew TW, Arceci RJ, Barnard D, Doyle J, Massey G, Perentesis J, Ravindranath Y, Taub J, Smith FO. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: A report from the Children's Oncology Group study A2971. Blood 118:6752-6759, 2011.
66. Xavier AC, Edwards H, Dombkowski AA, Balci TB, Berman JN, Dellaire G, Xie C, Buck SA, Matherly LH, Ge Y, Taub JW. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy. PLoSOne 6:e27486, 2011.
67. Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci RJ, Woods WG, Gamis AS. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer 118: 4806-4814, 2012.
68. Xie C, Edwards H, Xu X, LoGrasso SB, Buck SA, Matherly LH, Taub JW, Ge Y. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatric Blood and Cancer 59: 1245-1251, 2012.
69. Inaba H, Surprise HC, Stanley Pounds; Cao X, Howard SC, Ringwald-Smith K, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Rubnitz JE. Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer 118: 5989-5996, 2012.

70. Rubnitz JE, Pounds S, Cao X, Jenkins L; Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Hiroto Inaba H. Treatment outcome in older patients with acute myeloid leukemia. Cancer 118: 6253-6259, 2012.
71. Harper FWK, Penner LA, Peterson A, Albrecht TL, Taub J. Child Positive Dispositional Attributes, Parent Empathic Responses, and Children's Responses to Painful Pediatric Oncology Treatment Procedures. Journal of Psychosocial Oncology 30:593-613, 2012.
72. O'Brien MM, Dahl GV, Pounds S, Cao X, Raimondi SC, Lacayo NJ, Taub JW, Chang M, Weinstein HJ, Ravindranath Y, Inaba H, Campana D, Pui CH, Rubnitz JE. Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: A report from the AML02 multicenter trial and the Children's Oncology Group study POG 9421. Leukemia 27:731-734, 2013.
73. Seewald L, Taub JW, Maloney KW, Edward R McCabe ER. Acute Leukemias in Children with Down Syndrome. Molecular Genetics and Metabolism 107: 25-30, 2012.
74. Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY, Raimondi SC, Onciu M, Jacobsen J, Ribeiro RC, Dahl G, W. Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. Journal of Clinical Oncology 30:3625-3632, 2012.
75. Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis T, An WF, Li X, Bray MA, Thiollier C, Diebold L, Vokes MS, Moore CB, Bliss-Moreau M, VerPlank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Goldberg L, Birger Y, Izraeli S, Gamis AS, Smith FO, Woods WG, Taub J, Scherer CA, Bradner J, Goh BC, Mercher T, Carpenter AE, Gould RJ, Paul A. Clemons PA, Carr SA, Root DE, Schreiber SL, Stern AM, Crispino JD. Integrative screening approach identifies regulators of polyploidization and targets for acute megakaryocytic leukemia. Cell 150:575-89, 2012.
76. Harper FWK, Peterson AM, Uphold H, Albrecht TL, Taub JW, Orom H, Phipps S, Louis A. Penner LA. Longitudinal study of parent caregiving self-efficacy and parent stress reactions with pediatric cancer treatment procedures. Psycho-Oncology 22:1658-1664, 2013.
77. Wang G, He J, Zhao J, Yun W, Xie C; Taub JW, Dong Y, Kong W, Guo Y, Ge Y. Both class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PlosOne 7:e52095, 2012.
78. Caldwell JT, Edwards H, Dombkowski AA, Buck SA, Matherly LH, Ge Y, Taub JW. Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic leukemia. PlosOne 8:e68601, 2013.
79. O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Campana D, Rubnitz JE. Gemtuzumab ozogamicin is safe and effective at reducing minimal residual disease in childhood acute myeloid leukemia. Cancer 119:4036-4043, 2013.
80. Hales EC, Orr SM, Gedman AL, Taub JW, Matherly LH. Notch1 regulates AKT activation look (T308) dephosphorylation through modulation of the PP2A phosphatase in PTEN-

null T-cell acute lymphoblastic leukemia cells. Journal of Biological Chemistry 288:22836-22848, 2013.

81. Maligne S, Chlon T, Dore LC, Ketterling RP, Tallman MS, Paietta E, Gamis AS, Taub JW, Chou ST, Weiss MJ, Crispino JD, Figuerosa ME. Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood 122:e33-43, 2013.
82. Wang G, Edwards H, Buck SA, Qing WY, Taub JW, Ge Y, Wang Z. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide in high-risk neuroblastoma cells. PlosOne 8:e76662, 2013.
83. Xie C, Drenberg C, Edwards H, Inaba H, Xu X, Buck SA, Taub JW, Baker SD, Ge Y. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of brca1, chk1, and rad51. PlosOne 8:e79106, 2013.
84. Harper FWK, Goodlett BD, Trentacosta CJ, Albrecht TL, Taub JW, Phipps S, Penner L. Temperament, personality, and quality of life in pediatric cancer patients. Journal of Pediatric Psychology 39:459-468, 2014.
85. Peterson AM, Harper FWK, Albrecht TL, Taub JW, Orom H, Phipps S, Penner LA. Parent caregiver self-efficacy and child reactions to pediatric cancer treatment procedures. Journal of Pediatric Oncology Nursing. 31:18-27, 2014.
86. Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: Targeted therapy of γ -Secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cellular Signaling 26:149-161, 2014.
87. Cooper T, Alonzo TA, Gerbing RB, Perentesis J, Whitlock J, Taub JW, Horton TM, Gamis A, Meshinchi S, Razzouk B. AAML0523: A Report from the Children's Oncology Group on the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia. Cancer 120: 2482-2489, 2014.
88. Niu X, Wang G, Wang Y, J Caldwell JT, Edwards H, Xie C, Taub JW, Li C, Lin H, Ge Y. Acute Myeloid Leukemia Cells Harboring MLL Fusion Genes or with the Acute Promyelocytic Leukemia Phenotype Are Sensitive to the Bcl-2-selective Inhibitor ABT-199. Leukemia 28: 1557-1560, 2014.
89. Caldwell JT, Pitman H, Buck SA, Ge Y, Taub JW. Targeting the wee1 Kinase for Treatment of Pediatric Down Syndrome Acute Myeloid Leukemia. Pediatric Blood and Cancer 61: 1767-1773, 2014.
90. Qi W, Xie C, Li C, Caldwell JT, Edwards H, Taub JW, Wang Y, Lin H, Ge Y. CHK1 Plays a Critical Role in the Anti-leukemic Activity of the Wee1 Inhibitor MK-1775 in Acute Myeloid Leukemia Cells. Journal of Hematology & Oncology Aug 1;7:53. doi: 10.1186/s13045-014-0053-9, 2014.
91. Harper FWK, Peterson A, Albrecht TL, Taub J, Phipps S, Penner LA. Post-traumatic stress symptoms in parents of pediatric cancer patients: A mediational analysis. Journal of Traumatic Stress Disorders and Treatment. 39: 459-468, 2014.
92. Caldwell JT, Ge Y, Taub JW. Biology and Clinical Features of Acute Myeloid Leukemia in Children with Down Syndrome. Expert Review of Hematology 18: 1-10, 2014.

93. Harper FW, Peterson AM, Albrecht TL, Taub JW, Phipps S, Penner LA. Posttraumatic Stress Symptoms in Parents of Pediatric Cancer Patients: A Mediation Analysis. Journal of Trauma Stress Disorders and Treatment 3: pii: 1000133, 2014.
94. Karol SE, Coustan-Smith E, Cao X, Shurtleff SA, Raimondi SC, Choi JK, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D, Inaba H. Prognostic factors in children with acute myeloid leukemia and excellent response to remission induction therapy. British Journal of Haematology 168:94-101, 2015.
95. Xie C, Edwards H, Caldwell JT, Wang G, Taub JW, Ge Y. Obatoclox Potentiates the Cytotoxic Effect of Cytarabine on Acute Myeloid Leukemia Cells by Enhancing DNA Damage. Molecular Oncology 9: 409-421, 2015.
96. Hanmod SS, Wang G, Edwards H, Buck SA, Ge Y, Taub JW, Wang Z. Targeting Histone Deacetylases (HDACs) and Wee1 for Treating High-risk Neuroblastoma. Pediatric Blood and Cancer 62: 52-59, 2015.
97. Maloney KW. Taub JW, Ravindranath Y, Roberts I, Vyas P. Down Syndrome Preleukemia and Leukemia. Pediatric Clinics of North America 62: 121-137, 2015.
98. Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W; Taub JW, Zhao L, Ge Y. Synergistic antitumor interactions between mk-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Letters 356: 656-668, 2015.
99. Shaham L, Vendrarmini E, Ge Y, Pitman H, Goren Y, Tijssen M, Birger Y, McNulty M, Geron I, Schwartzman O, Goldberg L, Chou ST, Weiss MJ, Israel LL, Lellouche E, Michaeli S, Lellouche JP, Sredni B, Göttgens B, Crispino J, Taub JW*, Izraeli S*. MicroRNA-486-5p in the myeloid leukemias of Down Syndrome. Blood 125: 1292-1301, 2015. [*Co-corresponding authors]
100. Qi W, Zhang W, Edwards H, Chu R, Madlambayan GJ, Taub JW, Wang Z, Wang Y, Li C, Lin H, Ge Y. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer Biology Therapy 16:1784-1793, 2015.
101. Penner LA, Guevarra DA, Harper FWK, Taub J, Phipps S, Albrecht TL, Kross E. Self-distancing Buffers High Trait Anxious Pediatric Cancer Caregivers against Short- and Longer-term Distress. Clinical Psychological Science 4: 629-640, 2016.
102. Harper FWK, Peterson A, Albrecht TL, Taub J, Phipps S, Penner LA. Satisfaction with support versus size of network: differential effects of social support on psychological distress in parents of pediatric cancer patients. Reducing psychosocial distress among parents of pediatric cancer patients: Satisfaction with social support versus size of network. Psychooncology 25:551-558, 2016.
103. Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, Caldwell JT, Xiang S, Zhang X, Chu R, Wang J, Lin H, Taub JW, Ge Y. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clinical Cancer Research 22:4440-4451, 2016.
104. Zhao J, Niu X, Li X, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Ge Y. Inhibition of CHK1 Enhances Cell Death Induced by the Bcl-2-selective Inhibitor ABT-199 in Acute

Myeloid Leukemia Cells. Oncotarget 8: 6319-6329, 2016.

105. Trentacosta C, Harper FWK, Albrecht TL, Taub JW, Phipps S, Penner SA. Pediatric Cancer Patients' Treatment-Related Distress and Longer-Term Anxiety: An Individual Differences Perspective. Journal of Developmental and Behavioral Pediatrics 37:753-761, 2016.
106. Schwartz J, Niu X, Walton E, Hurley L, Lin H, Edwards H, Taub JW, Wang Z, Ge Y. Synergistic Anti-leukemic Interactions between ABT-199 and Panobinostat in Acute Myeloid Leukemia Ex Vivo. American Journal of Translational Research 8:3893-3902, 2016.
107. Liao Y, Niu X, Chen B, Edwards H, Xu L, Xie C, Lin H, Polin L, Taub JW, Ge Y, Qin Z. Piperlongumine Combined with Histone Deacetylase Inhibitor either in Combinatorial Treatment or Hybridized as Chimeric Molecules are Potent Antileukemic Agents against Acute Myeloid Leukemia Cells. Journal of Medicinal Chemistry 59:7974-7990, 2016.
108. Edwards H, Rubenstein M, Dombkowski AA, Caldwell JT, Chu R, Xavier AC, Thummel R, Neely M, Matherly LH, Ge, Y Taub JW. Gene Signature of High White Blood Cell Count in B-precursor Acute Lymphoblastic Leukemia. PlosOne 11(8):e0161539, 2016.
109. Navalkele P, Belgrave K, Altinok D, Bhambhani K, Taub JW, Zhihong J. Wang. Hypoalbuminemia Associated With Neuroblastoma: A Single Institution Experience. Annals of Pediatrics & Child Health 4:1115, 2016.
110. Zhao J, Xie C, Edwards H, Wang G, Taub JW, Ge Y. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells. Oncotarget 8:6319-6329, 2017.
111. Ma J, Li X, Su Y, Zhao J, Luedtke D, Epshteyn V, Edwards H, Wang G, Wang Z, Chu R, Taub JW, Lin H, Wang Y, Ge Y. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. Scientific Reports 7:41950, 2017.
112. Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, Chen K, Lin H, Taub JW, Ge Y. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2 selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy 7;2:17012. doi: 10.1038/sigtrans.2017.12.
113. Wang ZJ, Ge Y, Altinok D, Poulik J, Sood S, Taub JW, Edwards H, Kieran MW, Miller S. Concomitant use of panobinostat and re-irradiation in progressive DIPG: Report of 2 cases. Journal of Pediatric Hematology Oncology 39:e332-e335, 2017.
114. Taub JW, Berman JN, Hitzler JH, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS. Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Myeloid Leukemia of Down Syndrome (ML-DS): Results of the Children's Oncology Group (COG) Phase III AAML0431 Trial. Blood 129: 3304-3313, 2017.
115. Ning C, Liang M, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y. Targeting ERK Enhances the Cytotoxic Effect of the Novel PI3K and mTOR Dual Inhibitor VS-5584 in Preclinical Models of Pancreatic Cancer.

Oncotarget 8:44295-44311, 2017.

116. Marusak HA, Elrahal F, Peters CA, Kundu P, Lombardo MV, Calhoun VD, Goldberg EK, Cohen C, Taub JW, Rabinak CA. Mindfulness and dynamic functional neural connectivity in children and adolescents. Behavioural Brain Research 336:211-218, 2018.
117. Su Y, Li X, Ma J, Zhao J, Liu S, Wang G, Edwards H, Taub JW, Lin H, Ge Y. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochemical Pharmacology 148:13-26, 2018.
118. Marusak HA, Iadipalo AS, Harper FW, Elrahal F, Taub JW, Goldberg E, Rabinak CA. Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity framework to understanding cognitive, behavioral, and emotional outcomes. Neuropsychology Review 28:123-175, 2018.
119. Xavier AC, Epperla N, Taub JW, Costa LJ. Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. American Journal of Hematology 93:238-245 2018.
120. Sorge C, Costa LJ, Taub JW, S Cairo M, Xavier AC. Incidence and outcomes of rare paediatric non-hodgkin lymphomas. British Journal of Haematology. 184:864-867, 2019.
121. Hutchins KK, Savasan S, Thomas RL, Strathdee LA, Wang ZJ, Taub JW. Clinical trial enrollment is associated with improved follow-up rates among survivors of childhood cancer. Journal of Pediatric Hematology Oncology 41:e18-e23, 2019.
122. Marusak HA, Iadipalo AS, Paulisin S, Harper FW, Taub JW, Dulay K, Elrahal F, Peters C, Sala-Hamrick K, Crespo LM, Rabinak CA. Emotion-related brain organization and behavioral responses to socioemotional stimuli in pediatric cancer survivors with posttraumatic stress symptoms. Pediatric Blood and Cancer Sep 30:e27470, 2018.
123. Volk A, Liang K, Suraneni P, Li X, Zhao J, Bulic M, Marshall S, Pulakanti K, Malinge S, Taub J, Ge Y, Rao S, Bartom E, Shilatifard A, Crispino JD. A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis. Cancer Cell. 34:707-723. 2018.
124. Luedtke DA, Liu S, Su Y. Edwards H, Wang Y, Lin H, Taub JW, Ge Y. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukemia via Mcl-1. Journal of Cellular and Molecular Medicine 22:6099-6111, 2018.
125. Harper FWK, Albrecht TL, Trentacosta CJ, Taub JW, Phipps S, Penner LA. Understanding Differences in the Long-Term Psychosocial Adjustment of Pediatric Cancer Patients and their Parents: An Individual Differences Resources Model. Translational Behavioral Medicine 9:514-522, 2019.
126. Knight T, Luedtke D, Edwards H, Taub JW, Ge Y. A delicate balance- The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochemical Pharmacology 162:250-261, 2019.
127. Knight T, Edwards H, Taub JW, Ge Y. Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia. Cancer Management and Research 11:3197-3213, 2019.

128. de Smith AJ, Walsh KM, Morimoto LM, Francis SS, Gonseth S, Jeon S, Chen M, Sun H, Luna-Fineman S, Antillon F, Hansen HM, Kang AY, Smirnov I, Xiao X, Whitehead T, Barcellos LF, Sender L, Healy J, Laverdière C, Sinnett D, Taub JW, Birch JM, Thompson P, Pombo-de-Oliveira MS, Spector LG, DeWan AT, Mueller BA, Chiang C, Metayer C, Ma X, Wiemels JL. Heritable variation at the chromosome 21 gene *ERG* is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome. Leukemia. 33: 2746-2751, 2019.
129. Mast KJ, Taub JW, Alonzo TA, Gamis AS, Mosse CA, Mathew P, Berman JN, Wang YC, Jones HM, Campana D, Coustan-Smith E, Hitzler JK, Head DR. Pathologic Features of Down Syndrome MDS and AML: A Report From the Children's Oncology Group Protocol AAML0431. Archives of Pathology & Laboratory Medicine (in press 2019).
130. Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Sijana H, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia. Clinical Cancer Research 25:6815-6826, 2019.
131. Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Eng-Juh Yeoh A, Campana D, Wang L, Triplett B, Raimondi SC, Klcio J, Choi J, Pounds S, Pui CH. Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: The AML08 multicenter, randomized phase III trial. Journal of Clinical Oncology 37:2072-2081, 2019.
132. Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E, Metzner M, Kennedy A, Amstislavskiy V, Risch T, Bhayadia R, Samulowski D, Hernandez DC, Stoilova B, Iotchkova V, Opperman U, Scheer C, Yoshida K, Schwarzer A, Taub J, Crispino JD, Weiss MJ, Hayashi A, Taga T, Ito E, Ogawa S, Reinhardt D, Yaspp ML, Campbell PJ, Roberts I, Constantinescu S, Vyas P, Heckl D, Klusmann JH. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell 36: 1-16, 2019
133. Marusak HA, Harper FW, Taub JW, Rabinak CA. Pediatric cancer, posttraumatic stress and fear-related neural circuitry. International Journal of Hematologic Oncology 8(2):IJH17, 2019
134. Brown AL, de Smith AJ, Gant VU, Yang W, Scheurer ME, Walsh KM, Chernus JM, Kallsen NA, Peyton SA, Davies GE, Ehli EA, Winick N, Heerema NA, Carroll AJ, Borowitz MJ, Wood BL, Carroll WL, Raetz EA, Feingold E, Devidas M, Barcellos LF, Hansen HM, Morimoto L, Kang AY, Smirnov I, Healy J, Laverdière C, Sinnett D, Taub JW, Birch JM, Thompson P, Spector LG, Pombo-de-Oliveira MS, DeWan AT, Mullighan CG, Hunger SP, Pui CH, Loh ML, Zwick ME, Metayer C, Ma X, Mueller BA, Sherman SL, Wiemels JL, Relling MV, Yang JJ, Lupo PJ, Rabin KR. Inherited genetic susceptibility of acute lymphoblastic leukemia in Down syndrome. Blood 134:1227-1237, 2019.
135. Shatara M, Xavier AC, Dombkowski A, Cukovic D, Poulik JM, Altinok D, Ge Y, Taub JW. Monozygotic twins with neuroblastoma IVS and similar molecular profile: a case of likelihood twin-to-twin metastasis. British Journal of Cancer 121:890-893, 2019.

136. Wang T, Shatara M, Liu F, Knight T, Edwards H, Wang G, Lin H, Wang Y, Taub JW, Ge Y. Simultaneous co-targeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia. Signal Transduction and Targeted Therapy 4:44. doi: 10.1038/s41392-019-0076-3. eCollection 2019.
137. Shields JN, Hales EC, Ranspach LE, Luo X, Orr S, Runft D, Dombkowski A, Neely M, Matherly LH, Taub JW, Baker TR, Thummel R. Exposure of larval zebrafish to the insecticide Propoxur induced developmental delays that correlate with behavioral abnormalities and altered expression of *hspb9* and *hspb11*. Toxics 7(4). pii: E50. doi: 10.3390/toxics7040050, 2019.
138. Luedtke DA, Su Y, Ma J, Li X, Buck SA, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Lin H, Taub JW, Ge Y. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduction and Targeted Therapy. 2020 Feb 26;5:17. doi: 10.1038/s41392-020-0112-3. eCollection 2020.
139. Li X, Su Y, Hege K, Madlambayan G, Edwards H, Knight T, Polin L, Kushner J, Dzinic SH, White K, Yang J, Miller R, Wang G, Zhao L, Wang Y, Lin H, Taub JW, Ge Y. The HDAC and PI3K Dual Inhibitor CUDC-907 Synergistically Enhances the Antileukemic Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia. Haematologica (2020 Mar 12:haematol.2019.233445.
140. Yankelevich M, Hoogstra D, Abrams J, Chu R, Bhambhani K, Taub, JW. Delayed granulocyte colony-stimulating factor (G-CSF) administration after chemotherapy reduces total G-CSF doses without affecting neutrophil recovery in a randomized clinical study in children with solid tumors. Pediatric Hematology-Oncology 9:1-11, 2020.
141. Karol SE, Cooper TM, Mead PE, Crews KR, Panetta JC, Alexander TB, Taub JW, Lacayo NJ, Heym KM, Kuo DJ, Schiff DE, Bhojwani D, Ge Y, Kico JM, Ribeiro RC, Inaba H, Pui CH, Rubnitz JE. Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer 2020 Aug 18. doi: 10.1002/cncr.3315
142. Liu F, Kalpage HA, Wang D, Edwards H, Hüttemann M, Ma J, Su U, Carter J, Li X, Polin L, Kushner J, Dzinic SH, White K, Wang G, Taub JW, Ge Y. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation. Cancers 12(9):E2400, 2020.
143. Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, Hüttemann M, Taub JW, Ge Y. Targeting Multiple Signaling Pathways: The New Approach to Acute Myeloid Leukemia Therapy. Signal Transduction and Targeted Therapy 2020 Dec 18;5(1):288. doi: 10.1038/s41392-020-00361-x
144. Stewart R; Brahimi X, Iadipalo AS, Peters C, Harper FWK, Taub; JW, Rabinak CA; Marusak H. Childhood cancer-related posttraumatic stress and resilience have distinct effects on volume of the amygdala and hippocampus. Adversity and Resilience Science 2020
145. Carter J, Hege K, Edwards E, Huttemann M, Taub JW, Ge Y. Targeting Mitochondrial Respiration for the Treatment of Acute Myeloid Leukemia. Biochemical Pharmacology

2020 Oct 1;114253.

146. Levy C, Shienboim D, Parikh S, Parikh R, Menuchin A, Shapira G, Kapitansky O, Rupp S, Shaham L, Golan T, Elgavish S, Nevo Y, Bell RE, Malcov H, Shomron N, Taub J, Izraeli S. Slow transcription of the 99/let7/125 cluster results in differential miRNA expression and promotes melanoma phenotypic plasticity. Journal of Investigative Dermatology 2021 Jun 26:S0022-202X(21)01406-8.
147. Gadgeel M, AlQanber B, Buck B, Taub JW, Ravindranath Y, Savaşan S. Aberrant myelomonocytic CD56 expression in Down Syndrome is frequent and not associated with leukemogenesis. Annals of Hematology 100:1695-1700, 2021.
148. Qiao X, Ma J, Knight T, Su Y, Edwards H, Polin L, Li J, Kushner J, Dzinic SH, White K, Wang J, Lin H, Wang Y, Wang L, Wang G, Taub JW, Ge Y. The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood Cancer Journal. 11:111, 2021. doi: 10.1038/s41408-021-00502-7.
149. Marusak HA, Iadipaolo AS, Cohen C, Goldberg E, Taub JW, Harper FWK, Bluth MH, Rabinak CA. Martial arts-based therapy reduces pain and distress among children with chronic health conditions and their siblings. Journal of Pain Research 13:3467-3478, 2020.
150. Hitzler JK, Alonzo T, Gerbing RB, Beckman A, Hirsch B, Raimondi S, Chisholm K, Viola SA, Eidenschink Brodersen L, Loken MR, Tong RS, Druley TE, O'Brien MM, Hijjiya N, Heerema-McKenney AE, Wang J, Schore R, Taub JW, Gamis AS, Kolb EA, Berman JN. High-dose AraC is Essential for the Treatment of ML-DS Independent of Post-Induction MRD: Results of COG AAML1531. Blood 2021 Jul 28:blood.2021012206.

Case Reports

1. Fenton DS, Taub JW, Amundson GM, Cushing B: Renal cell carcinoma in a child occurring two years after chemotherapy for neuroblastoma. American Journal of Roentgenology 161:165-1666, 1993.
2. Taub JW, Mohamed AN, Wolman SR, Bawle EV, Ravindranath Y: Acute lymphoblastic leukemia in a 46,XY/47,XXY mosaic male: clonal origin of leukemia in the XY-bearing stem cell line. American Journal of Diseases of Children 147:1254-1255, 1993.
3. Jadhav M, Langenburg S, Fontanesi J, Slovis TL, Taub JW: Hepatoblastoma with spinal metastases. Journal of Pediatric Hematology Oncology 22:524-526, 2000.
4. Sarnaik A, Mahajan P, Taub J: Morning report at Children's Hospital of Michigan. Synopsis: A Current Survey of World Literature in Pediatrics 2:61-64, 2000.
5. Chandler S, Westphal SM, Zak IT, Bloom DA, Zingas AP, Joyrich RN, Littrup PJ, Taub JW, Getzen TM: Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clinical Nuclear Medicine 29:416-418, 2004.
6. Inaba H, Londero M, Maurer SH, Onciu M, Ge Y, Taub J, Rubnitz JE, Raimondi SC. Acute megakaryoblastic leukemia without the GATA1 mutation following transient myeloproliferative disorder in an infant without Down syndrome. Journal of Clinical Oncology 29:e230-233, 2011.

7. Ubaidulhaq M, Ahmed SU, Taub JW. Abdominal pain in a teen with sickle cell disease: What's the source? Consultant for Pediatricians 14:172-175, 2015.
8. Shatara M, Regling K, Sabo C, Figueroa M, Taub JW, Rajpurkar M. Ethosuximide – induced thrombocytopenia: a case report. Journal of Pediatric Hematology Oncology 41:420-421, 2019.
9. Persaud Y, Al-Antry E, Shamoun M, Chitlur M, Taub JW. Childhood B-Cell Acute Lymphoblastic Leukemia Following SARS CoV-2 Infection: A Potential Second “Hit” in Leukemogenesis. Journal of Pediatric Hematology Oncology 2020 in press
10. Persaud Y, Seddiq M, Wu YM, Robinson DR, Poulik J, Altinok D, Roarty JD, Mody R, Taub JW. Unusual Clinical Behavior of a Very Late Retinoblastoma Relapse in a Patient with a Germline RB Mutation. Pediatric Blood and Cancer 2021 Aug;68(8):e29064.

Editorial/Commentaries

(Inside Blood)

1. Taub JW. Down syndrome and megakaryocytic leukemia/transient myeloproliferative disorder-When does it begin? Blood 101:4228, 2003.
2. Taub JW. Down Syndrome and Leukemia-It's in the Cards. Blood 103: 2434, 2004.
3. Taub JW. Of mice and Down syndrome. Blood 111: 472, 2008.
4. Taub JW. Mutant neonatal GATA1 clones under the radar. Blood 122:3851-3, 2013.

Letters to the Editor

1. Taub JW, Warriar I, Lusher JM, Holtkamp C, Beardsley DS: Antiplatelet antibodies in childhood Idiopathic Thrombocytopenic Purpura. American Journal of Hematology 51:328, 1996. (Letter to the Editor).
2. Savasan S, Ozgonenel, Taub JW, Hamre M. Elevated serum cobalamin levels in childhood autoimmune and drug-induced neutropenia. British Journal of Haematology 124:253-254, 2004.
3. Taub JW. Here's how MAD has influenced me over the past 47 years. MAD Magazine December 2018.
4. Taub, Ge Y, Xavier AC. COVID-19 and Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer May 13:e28400, 2020.
5. Knight TE, Holly Edwards H, Taub JW, Ge Y. MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition. [Commentary] EBioMedicine 7:103488, 2021.
6. Knight TE, Ge Y, Taub JW, Hitzler J, Krueger J. When it Comes to Drug Access, Should Children Be Considered Small Adults? Countering Coverage Denials of FLT3 Inhibitors in Children with FLT3-ITD AML. [Commentary] Pediatric Blood and Cancer (2021 in press).

NON-PEER-REVIEWED PUBLICATIONS:

1. Burke S, Taub J, Fischer H. Food for thought. Contemporary Pediatrics 9:142-143, 1992.
2. Burke S, Taub J, Fischer H. Who's zoo. Contemporary Pediatrics 10:100-101, 1993.
3. Fischer H, Taub J. Shades of Gray. Consultant for Pediatricians 5: 390-391, 2006.

Citation/Editorial Comment

1. Taub JW, Matherly LH, Stout ML, et al: Enhanced metabolism of 1- β -D-arabino-furanosylcytosine in Down Syndrome cells: a contributing factor to the superior event free survival of Down Syndrome children with acute myeloid leukemia. (citation). [published in Blood 87:3395-3403,1996]. Reviewed in 1997 Year Book of Oncology, (Ozols RF, Editor), Mosby Publ., New York, 1997, pp.214-5.
2. High leukaemia cure rate in Down's syndrome explained. Lancet Oncology. 6:134, 2005. [Comment on: Gata1, cytidine deaminase and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. Journal of the National Cancer Institute 97:226-231, 2005]
3. Crispino JD. Up and down in Down syndrome: AMKL. Blood 107: 1251-2, 2006. [Commentary on: Differential gene expression, GATA1 target genes and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 107: 1570-1581, 2006]
4. Ross JA. Looking for leukemia clues in of all places....meconium! Pediatric, Blood and Cancer. 49:607-608, 2007. [Commentary on: Association between prenatal pesticide exposures and the generation of leukemia-associated t(8;21). Pediatric, Blood and Cancer 49:624-628, 2007; Karmanos Cancer Institute Center Director's Quarterly Research Award 2008]
5. Taub JW. Early T-cell precursor acute lymphoblastic leukaemia. Lancet Oncology 10: 105-106, 2009.
6. Taub JW, Ravindranath Y. What's up with Down syndrome and leukemia-A lot! Pediatric Blood and Cancer 57:1-3, 2011.
7. Grimes HL, Meyer SE. A 2-way miRror of red blood cells and leukemia. Blood 125: 1202-1203, 2015 [Commentary on: MicroRNA-486-5p in the myeloid leukemias of Down Syndrome. Blood 125: 1292-1301, 2015] Publication #99 above
8. ASH Clinical News June 2017 Paper Spotlight. Predicting survival outcomes for children with Down syndrome and AML or MDS [Commentary on: Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Myeloid Leukemia of Down Syndrome (ML-DS): Results of the Children's Oncology Group (COG) Phase III AAML0431 Trial. Blood 2017 129: 3304-3313, 2017] Publication #114 above.
9. Shand JC. Looking up for AML in Down syndrome. Blood 129: 3273-3274, 2017 [Commentary on Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Myeloid Leukemia of Down Syndrome (ML-DS): Results of the Children's Oncology Group (COG) Phase III AAML0431 Trial. Blood 129: 3304-3313]. Publication #114 above.

10. ASH Clinical News September 2017. Rewriting the Rules of Informed Consent. Citation of Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Myeloid Leukemia of Down Syndrome (ML-DS): Results of the Children's Oncology Group (COG) Phase III AAML0431 Trial. Blood 2017 129: 3304-3313, 2017] Publication #114 above.

Book Authorships, Editorships, and Chapters

1. Ravindranath Y, Taub JW. Leucemia en el lactante. In: Tratado de Oncología Pediátrica. Editors: Sierrasesúмага L, Klussmann FA, Bernaola E, Patiáo A, Julián MS. Pearson Prentice Hall 2005.
2. Taub JW, Ge Y, Ravindranath Y. Down Syndrome and Acute Myeloid Leukemia: An Unique Genetic Susceptibility to Chemotherapy. In: Molecularly-Targeted Therapy for Childhood Cancer. Eds: Houghton PJ, Arceci RJ. (Springer NY, 2010)
3. Fontanesi J, Taub J, Kirkpatrick JP, Halperin EC. Retinoblastoma. In: Pediatric Radiation Oncology. Eds: Halperin EC, Constine LS, Tarbell NJ, Kun LE. (Lippincott Williams & Wilkins, Philadelphia, PA, 2011)
4. Xavier AC, Ge Y, Taub JW. Down syndrome and leukemia. In: Cancer in Children and Adults with Intellectual Disabilities: Current Research Aspects. Eds: Satgé D, Merrick J. (Nova Science Publishers, 2011)
5. Taub JW, Sorrell A, Whitlock JA. Leukemias in Patients with Down Syndrome. In: Childhood Leukemias. Ed: Pui CH. (Cambridge University Press, 2012)
6. Xavier AC, Ge Y, Taub JW. Etiology of Leukemia in Children with Down Syndrome. In: Etiology of Acute Leukemias in Children. Ed: Mejia-Arangure. (Springer, 2016)

PRESENTATIONS:

1. Invited and/or Refereed International or National Meetings.

1. Taub JW, Goyette G, Buck S, Ravindranath Y. Autosomal dominant inheritance of congenital pure red blood cell aplasia with normal adenosine deaminase activity. Presented at the Annual Meeting of the Society for Pediatric Research, Baltimore, MD, May 4-8, 1992. Ped Res 31(4):1461, 1992.
2. Taub JW, Warrier I, Holtkamp C, Beardsley DS, Lusher JM. Autoantibodies against platelet antigens IIb/IIIa in children with immune thrombocytopenia (ITP): do they predict the course of thrombocytopenia? Presented at the XIVth Congress of The International Society on Thrombosis and Haemostasis, New York City, NY, July 4-9, 1993. Thromb Haemost 69 (6):565,1993.
3. Ravindranath Y, Taub J, Krischer J, Weinstein H, for the Pediatric Oncology Group (POG). Acute myeloid leukemia (AML) in Down Syndrome (DS): superior response to regimens with high dose arabinosyl cytosine (ara-C). Presented at the 8th Symposium Molecular Biology of Hematopoiesis, Basel, Switzerland, July 9-13, 1993.
4. Taub JW, Warrier I, Holtkamp C, Beardsley DS, Lusher JM. Autoantibodies against platelet antigens IIb/IIIa in children with immune thrombocytopenia (ITP) does not predict

the course of thrombocytopenia. Presented at the 6th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Sept. 30-Oct. 3, 1993, Chicago, IL.

5. Abella EM, Taub J, Schultz K, Richards D, Ravindranath Y. Treatment of familial erythrophagocytic lymphohistiocytosis (FEL) with cyclosporin A (CSA). Presented at the 6th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Sept. 30 - Oct. 3, 1993, Chicago, IL.
6. Ravindranath Y, Taub J, Krischer J, Weinstein H, for the Pediatric Oncology Group. Acute Myeloid Leukemia (AML) in Down Syndrome (DS): superior response to regimens with high-dose Arabinosyl Cytosine (Ara-C). Presented at the Gordon Conference - Purines, Pyrimidines, and Related Substances, July 4-9, 1993, Newport, Rhode Island.
7. Matherly LH, Wong SC, Angeles SM, Taub JW, Smith GK. Distribution of the reduced folate carrier (RFC) versus the high affinity membrane folate binding protein (mFBP) in human tumors and tissues. Presented at the 35th Annual Meeting of the American Association of Cancer Research, San Francisco, CA, April 10-13, 1994. Proc Am Assoc Cancer Res 35:1825a, 1994.
8. Taub JW, Ravindranath Y. Superior disease free survival of Down Syndrome children with Acute Myeloid Leukemia associated with enhanced sensitivity to Cytarabine and Daunorubicin - a hypothesis. Presented at the International Down Syndrome Research Conference, Charleston, SC, April 10-13, 1994.
9. Taub JW, Matherly LH, Buck SA, Stout M, Ravindranath. Enhanced formation of cytarabine triphosphate (ara-CTP) in Down Syndrome cells: Possible explanation for superior disease free survival of Down Syndrome children with acute myeloid leukemia. Presented at the 1994 Annual Meeting of American Society of Hematology, Dec. 2-6, 1994, Nashville, TN. Blood 84 (suppl. 1): p. 515a, abstract # 2047, 1994.
10. Taub JW, Ravindranath Y, Stout M, Buck SA, Matherly LH. Enhanced metabolism of cytarabine contributes to the superior survival rate of Down Syndrome children with acute myeloid leukemia. Presented at the 36th Annual Meeting of the American Association of Cancer Research, March 18-22, 1995, Toronto, Canada. Proc Am Assoc Cancer Res 36:2407a, 1995.
11. Taub JW, Matherly LH, Buck SA, Stout M, Ravindranath Y. Enhanced formation of cytarabine triphosphate (ara-CTP) in Down Syndrome cells: possible explanation for superior disease free survival of Down Syndrome children with acute myeloid leukemia. Presented at the 1995 APS/SPR Meeting, May 7-11, 1995, San Diego CA. Ped Res 37(4):167A, abstract # 987, 1995.
12. Taub JW, Roarty J, DeCamillo D, Fontanesi J, Slovis T, Trese M, Ravindranath Y. Platinum based chemotherapy protocols are an effective upfront therapy for newly diagnosed bilateral retinoblastoma. Presented at the XXVIIth Meeting of the International Society of Pediatric Oncology, Oct. 10-14, 1995, Montevideo, Uruguay. Med Ped Oncol 25:320; abstract P-168, 1995.
13. Matherly LH, Taub JW, Ekizian R, Wong SC, Ravindranath Y. Increased frequency of heterogeneous expression of elevated dihydrofolate reductase (DHFR) in T-cell versus B-lineage acute lymphocytic leukemia (ALL) in children. Presented at the 1996 Annual Meeting of American Association of Cancer Research, April 1996, Washington D.C. Proc Am Assoc Cancer Res 37:381, abstract # 2603, 1996.

14. Stout ML, Taub J, Buck SA, Ravindranath Y. Determination of initial in vitro drug sensitivity in childhood leukemias by a modified tetrazolium dye method. Presented at the 1996 Annual Meeting of American Association of Cancer Research, April 1996, Washington D.C. Proc Am Assoc Cancer Res 37:201, abstract # 1370, 1996.
15. Taub JW, Stout M, Buck SA, Vega RA, Becton DL, Ravindranath Y. Enhanced in vitro sensitivity of Down Syndrome myeloblasts to cytarabine and daunorubicin utilizing the MTT colorimetric assay. Presented at the Spring 1996 Meeting of the Pediatric Oncology Group (POG), April 18-21, 1996, St. Petersburg, FL.
16. Taub JW, Stout M, Buck SA, Vega RA, Becton DL, Ravindranath Y. Enhanced in vitro sensitivity of Down Syndrome myeloblasts to cytarabine and daunorubicin utilizing the MTT colorimetric assay. Presented at the 1996 Annual Meeting of the American Society of Clinical Oncology, May 18-21, 1996, Philadelphia, PA. Proc Amer Soc Clin Oncol 15:367, abstract # 1086, 1996.
17. Taub JW, Ravindranath Y, Ekizian R, Wong SC, Buck SA, Simpson P, Matherly LH. Elevated dihydrofolate reductase levels are a common finding in African American children with B-precursor acute lymphoblastic leukemia at diagnosis: a potential mechanism leading to treatment failure. Presented at the 1996 Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 6-10, 1996. (Blood 88(10; suppl.1):166a,abstract # 652,1996.)
18. Dugan MC, Tabaczka P, Taub J. P21^{NAF-1}, Bax, and Bcl-2 in Hodgkin's Disease of childhood. Presented at the 1997 Annual Meeting of United States and Canadian Academy of Pathology. March 1-7, 1997, Orlando FL. Lab Invest 76(1):124a, (abstract # 720), 1997.
19. Taub JW, Ravindranath Y, Ekizian R, Wong SC, Buck SA, Simpson P, Matherly LH. Elevated dihydrofolate reductase levels are a common finding in African American children with B-precursor acute lymphoblastic leukemia at diagnosis: a potential mechanism leading to treatment failure. Presented at the 1997 Spring Meeting of the Pediatric Oncology Group, April 18-20, 1997, St. Petersburg FL.
20. Wozniak MM, Ellis DA, Taub JW. Neuropsychological abnormalities in childhood acute lymphoblastic leukemia (ALL) survivors treated with systemic methotrexate without craniospinal irradiation. Presented at the 10th Annual Meeting of the American Society of Pediatric Hematology-Oncology, Sept. 18-20, 1997, San Diego CA. J Pediatr Hematol-Oncol 19(4):376, abstract # 625, 1997.
21. Taub JW, Huang X, Stout ML, Buck S, Massey G, Becton D, Matherly LH, Ravindranath Y. Differences in expression of chromosome 21 localized genes between Down syndrome and non-Down syndrome myeloblasts and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Presented at the 1997 Annual Meeting of the American Society of Hematology, San Diego, CA, Dec. 5-9, 1997. Blood 90:496a, abstract # 2212, 1997.
22. Huang X, Stout ML, Buck SA, Ravindranath Y, Matherly LH, Taub JW. Cystathionine- β -synthase cDNA transfection alters the sensitivity of CCRF-CEM leukemia cells to cytosine arabinoside: a model of Down Syndrome and leukemia. Presented at the American Association of Cancer Research Annual Meeting, March 28-April 1, 1998, New Orleans LA. Proc Am Assoc Cancer Res 39:3181a, 1998.

23. Zhang L, Taub JW, Wong SC, Williamson M, Ravindranath Y, Matherly LH. Reduced folate carrier (RFC) gene expression in cultured cells and childhood acute lymphoblastic leukemia (ALL) by competitive polymerase chain reaction (cPCR) assay. Presented at the Annual Meeting of the American Association of Cancer Research, March 28-April 1, 1998, New Orleans LA. Proc Am Assoc Cancer Res 39:2244a, 1998.
24. Ravindranath Y, Taub JW. Down Syndrome and AML: a model for curing leukemia? Presented at the 3rd Symposium on Drug Resistance in Leukemia/Lymphoma, Amsterdam, March 4-7, 1998. Leukemia 12:266, abstract # 043, 1998.
25. Hamre M, Buck S, Taub JW, Stout M, Chang M, Becton D, Weinstein H, Ravindranath Y. P-glycoprotein (p-GP) expression and drug sensitivity/resistance in childhood acute myeloid leukemia (AML). Presented at the 3rd Symposium on Drug Resistance in Leukemia/Lymphoma, Amsterdam, March 4-7, 1998. Leukemia 12:267, abstract # 046, 1998.
26. Taub JW. The molecular basis of chemotherapy sensitivity of Down Syndrome children with leukemia. Leukemia Society of American Translational Research Progress Review Meeting, Washington DC, Sept. 24-25, 1998.
27. Shah SJ, Taub JW, Radewan TL, Fu W, Moore D, Pollock BH, Zhang L, Amylon M, Behm FG, Pullen J, Ravindranath Y, Matherly LH. Relationship of p15 and p16 gene deletions to elevated dihydrofolate reductase (DHFR) in childhood acute lymphoblastic leukemia (ALL). Presented at the Annual Meeting of the American Society of Hematology, Miami Beach, FL, Dec. 4-8, 1998. Blood 92 (suppl.1):p. 220a, abstract # 902, 1998.
28. Matherly LH, Taub JW, Zhang L, Zhang Z, Witt T, Hukku B, Shah S, Ravindranath Y. Acute lymphoblastic leukemia (ALL) cells with t (12;21) exhibit increased levels and activity of human reduced folate carrier (hRFC). Presented at the Annual Meeting of the American Association for Cancer Research. Philadelphia PA, Apr. 10-14, 1999. Proc Am Assoc Cancer Res 40:1942a, 1999.
29. Taub JW, Roarty JD, Fontanesi J, Slovis TL, Trese MT, Ravindranath Y. Neoadjuvant chemotherapy and local therapy improves the outcome of eye salvage in retinoblastoma: The Children's Hospital of Michigan Experience, 1981-1998. Presented at the International Congress of Ocular Oncology, Philadelphia, PA, May 2-6, 1999.
30. Taub JW, Ge Y, Huang X, Stout ML, Dutcher JA, Mohammad RM, Ravindranath Y, Matherly LH. Factors regulating expression of the chromosome 21-localized gene, cystathionine beta synthase, in Down Syndrome myeloblasts and its role in the high event-free survival rates of Down Syndrome patients with acute myeloid leukemia. Presented at the 41st Annual Meeting of the American Society Of Hematology meeting, New Orleans, LA, Dec. 3-7, 1999. Blood 94 :382a, abstract # 1698, 1999.
31. Gifford AJ, Whetsine JR, Bark KS, Kulkarni JS, Taub JW, Haber M, Norris MD, Matherly LH. Mutations in the reduced folate carrier gene (RFC) in childhood acute lymphoblastic leukemia (ALL). Presented at the Annual Meeting the American Association for Cancer Research, April 1-5, 2000, San Francisco, CA. Proc Am Assoc Cancer Res 41:758, abstract # 4820, 2000.
32. Ge Y, Huang X, Stout ML, Ravindranath Y, Matherly LH, Taub JW. Increased cytarabine (Ara-C) phosphorylation and drug activity in cystathionine β -synthase (CBS) transfected

CCRF-CEM cells is associated with posttranscriptional activation of deoxycytidine kinase (DCK). Presented at the Annual Meeting the American Association for Cancer Research, April 1-5, 2000, San Francisco, CA. Proc Am Assoc Cancer Res 41:863, abstract # 5483, 2000.

33. Ravindranath Y, Taub JW. Down syndrome (DS) and Acute Myeloid Leukemia (AML): a model for understanding the biochemical basis for increased drug sensitivity. Presented at the 2nd International Symposium on Childhood MDS. May 11-14, 2000, Hindsgavl Castle-Fyn, Denmark.
34. Massey G, Zipursky A, Doyle J, Taub J, Ravindranath Y, Weinstein H. Presenting clinical and laboratory features of transient myeloproliferative disorders (TMD) in neonates with Down Syndrome (DS): a Pediatric Oncology Group study. Presented at the Annual Meeting of The American Society of Pediatric Hematology/Oncology, Sept. 14-16, 2000, Minneapolis, MN. J Pediatr Hematol Oncol 22:383, 2000 (abstract # 646).
35. Massey G, Zipursky A, Doyle J, Taub J, Ravindranath Y, Weinstein H. Transient myeloproliferative disorder (TMD) in neonates with Down Syndrome (DS): early death and hepatic failure; a Pediatric Oncology Group study. Presented at the Annual meeting of The American Society of Pediatric Hematology/Oncology, Sept. 14-16, 2000, Minneapolis, MN. J Pediatr Hematol Oncol 22:383, 2000 (abstract # 647).
36. Czarnecki PM, Brooks DG, Rao R, Taub JW, Stambolian DE, Bawle EV. Three generation family with hereditary hyperferritinemia-cataract syndrome carrying a missense mutation in the L-ferritin gene. Presented at the Annual Meeting of the American Society of Human Genetics, Philadelphia, PA, Oct. 3-7, 2000. Am J Hum Genet 67(suppl. 2):389, abstract # 2183, 2000.
37. Taub JW, Kaspers GJL, Rots MG, Van Zantwijk CH, Matherly LH, Ravindranath Y. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methotrexate (MTX) sensitivity of childhood B-precursor acute lymphoblastic leukemia (BP-ALL). Presented at the 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, Dec. 1-5, 2000. Blood 96(11):100a, abstract # 428, 2000.
38. Massey GV, Zipursky A, Doyle JJ, Taub JW, Ravindranath Y, Chang MN, Weinstein HJ. A prospective study of the natural history of transient myeloproliferative disorder (TMD) in neonates with Down Syndrome (DS): A Pediatric Oncology Group (POG) Study. Presented at the 42nd annual meeting of the American Society of Hematology, San Francisco, CA, Dec. 1-5, 2000. Blood 96(11):744a, abstract # 3220, 2000.
39. Ravindranath Y, Kaspers GJL, Rots MG, van Zantwijk CH, Taub JW, Matherly LH. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methotrexate (MTX) sensitivity in childhood B-precursor Acute Lymphoblastic Leukemia (BP-ALL). Presented at the 4th International Symposium on Drug Resistance in Leukemia and Lymphoma, March 7-10, 2001, Amsterdam, The Netherlands. Leukemia 15(3):496, abstract # P-03, 2001
40. Konrad M, Ge Y, Naber J, Scott JS, Matherly LH, Taub JW. Leukemic clones are frequently present in neonatal blood samples of children with acute lymphoblastic leukemia (ALL). Presented at the 92nd Annual Meeting of the American Association of Cancer Research, New Orleans, LA, March 24-28, 2001. Proc Am Assoc Cancer Res 42:408, abstract # 2196, 2001.

41. Taub JW, Roarty J, Trese M, Fontanesi J, Ravindranath Y. Allergic reactions to carboplatin with prolonged use in Retinoblastoma patients. Tenth annual International Symposium on Retinoblastoma, Ft. Lauderdale, FL, May 4, 2001.
42. Roarty J, Taub JW, Trese M, Fontanesi J, Ravindranath Y. Recalcitrant Retinoblastoma growth after one-drug chemotherapy in patients < 1 year. Tenth annual International Symposium on Retinoblastoma, Ft. Lauderdale, FL, May 4, 2001.
43. Roarty J, Taub JW, Trese M, Fontanesi J, Ravindranath Y. Orbital recurrence of retinoblastoma in the opposite orbit. Tenth annual International Symposium on Retinoblastoma, Ft. Lauderdale, FL, May 4, 2001.
44. Ravindranath Y, Kaspers GJL, Rots MG, van Zantwijk CH, Taub JW, Matherly LH. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methotrexate (MTX) sensitivity of childhood B-precursor acute lymphoblastic leukemia (Bp-ALL). Presented at the 33rd meeting of the International Society of Paediatric Oncology (SIOP). Med Pediatr Oncol 37(3): 254, abstract # P184, 2001.
45. Ge Y, Jensen TL, Weinstein HJ, Becton DL, Massy GV, Ravindranath Y, Matherly LH, Taub JW. Multifactorial mechanisms accounting for increased sensitivity of Down Syndrome myeloblasts to cytosine arabinoside. Presented at the Annual Meeting of the American Association for Cancer Research Apr 6-10, 2002, San Francisco, CA. Proc Am Assoc Cancer Res 43:abstract #5406, 2002.
46. Massey G, Zipursky A, Doyle JJ, Taub J, Chang MN, Ravindranath Y, Weinstein HJ. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): A Pediatric Oncology Group (POG) study. Presented at the Annual Meeting of the American Society of Hematology Dec 6-10, 2002. Blood (100): 87a, abstract 321, 2002.
47. Ge Y, Jensen TL, Matherly LH, Taub. Physical and functional interactions of Sp1/3 and USF1/2 required for human deoxycytidine kinase promoter activity in HepG2 cells. Presented at the Annual Meeting of the American Association for Cancer Research July 11-14, 2003, Washington, D.C. Proc Am Assoc Cancer Res 44: abstract #2372, 2003.
48. Flatley RM, Payton SG, Whetstone JR, Taub JW, Matherly LH. Primary acute lymphoblastic leukemia cells (ALL) use a novel promoter and 5' non-coding exon for the human reduced folate carrier (hRFC) that encodes a modified carrier translated from an upstream translational start. Presented at the Annual Meeting of the American Association for Cancer Research July 11-14, 2003, Washington, D.C. Proc Am Assoc Cancer Res 44: abstract # 2618, 2003.
49. Taub JW, Mundschau G, Ge Y, Poulik J, Qureshi F, Jensen TL, Matherly LH, James J, Weschler J, Crispino JD. Prenatal origin of GATA1 mutations as an initiating step in the development of leukemia in Down syndrome. Presented at Annual Meeting of the American Association for Cancer Research March 27-31, 2004, Orlando, FL. Proc Am Assoc Cancer Res 45: abstract #3943, 2004.
50. Ge Y, Tatman-Lily D, Stout ML, Buck S, Ravindranath Y, Matherly LH, Taub JW. Mutations of the GATA-1 transcription factor alter the cytosine arabinoside (ara-C) sensitivity of Down syndrome (DS) megakaryoblasts. Presented at Annual Meeting of the American Association for Cancer Research March 27-31, 2004, Orlando, FL. Proc Am Assoc Cancer Res 45: abstract #3099, 2004.

51. Liu M, Flatley RM, Payton SG, Whetstone JR, Ge Y, Taub JW, Matherly LH. The human reduced folate carrier promoter B is a major promoter in childhood acute lymphoblastic leukemia cells and is regulated by Sp, USF, and Ikaros proteins Presented at Annual Meeting of the American Association for Cancer Research March 27-31, 2004, Orlando, FL. Proc Am Assoc Cancer Res 45: abstract #3100, 2004.
52. Payton SG, Ge Y, Flatley RM, Taub JW, Matherly LH. The human reduced folate carrier (hRFC) in childhood acute lymphoblastic leukemia (ALL) cells is regulated by a novel A1/A2 non-coding region and promoter including multiple E-box consensus elements Presented at Annual Meeting of the American Association for Cancer Research (AACR) March 27-31, 2004, Orlando, FL. Proc Am Assoc Cancer Res 45: abstract #4620, 2004.
53. Sharathkumar A, Patel M, Thomas R, Ravindranath Y, Taub JW. Outcome of children with hyperdiploid acute lymphoblastic leukemia-an apparent predisposition for extramedullary relapse and high salvage rate. A Single institution experience. Presented at Annual Meeting of the American Society of Hematology (ASH) Dec. 3-7, 2004, San Diego, CA. Blood abstract #1956, 2004.
54. Cline RJ, Penner LA, Albrecht TL, Ruckdeschel J, Peterson AM, Taub JW, Harper FK, Simon LJ. Who's in the room? Relationships between parents' communication and children's stress during painful cancer treatment procedures. To be presented at the Annual Meeting of the Society of Behavioral Medicine. Boston, MA, April 13-16, 2005.
55. Ge Y, Jensen TL, Tatman DA, Stout ML, Buck SA, Ravindranath Y, Matherly LH, Taub JW. GATA1 target genes and the differential chemotherapy sensitivity of Down syndrome and non-Down syndrome megakaryoblasts. Presented at Annual Meeting of the American Association for Cancer Research (AACR) Anaheim, CA, April 16-20, 2005. Proc Am Assoc Cancer Res 46: abstract #4339, 2005.
56. Liu M, Ge Y, Payton SG, Flatley RM, Aboukameel A, Mohammad R, Taub JW, Matherly LH. Transcriptional and posttranscriptional regulation of the human reduced folate carrier and methotrexate uptake in childhood acute lymphoblastic leukemia. Presented at the Annual Meeting of the American Association for Cancer Research (AACR) Anaheim, CA, April 16-20, 2005. Proc Am Assoc Cancer Res 46: abstract #4726, 2005
57. Taub JW, Ostrea EM Jr., Bielawski D, LaFiura KM, Ge Y. Prenatal pesticide exposure and the generation of leukemia-associated translocations detected in cord blood samples. Presented at the Annual Meeting of the Society for Pediatric Research 2005, Washington, D.C., May 14-17, 2005. Pediatr Blood Cancer 44: 558 (abstract #1139), 2005
58. Ostrea EM Jr., Silao CL, Cutiongco E, Villanueva-Uy E, Padilla CD, Taub JW, Ge Y, LaFiura K. Fetal exposure to environmental pesticides and associated genetic abnormalities. Presented at the Annual Meeting of the Society for Pediatric Research 2005, Washington, D. C., May 14-17, 2005. [abstract 606]
59. Rubnitz J, Razzouk B, Bowman P, Dahl G, Lacayo N, Taub J, Ravindranath Y, Meshinchi S, Airewele G, Lensing S, Pounds S, Ribeiro R, Pui CH, Coustan-Smith E, Campana D. Improved remission induction rate of childhood AML: Preliminary results of the AML02 trial. Presented at the Annual Meeting of the American Society of Hematology. Dec 2005.

60. Ge Y, LaFiura KM, Matherly LH, Taub JW, Ravindranath Y. Identification and Characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia. Presented at the Annual Meeting of the American Association for Cancer Research, Washington, D.C., Apr. 2006. [abstract 4326]
61. Ge Y, Haska C, LaFiura K, Devidas M, Linda S, Taub JW, Matherly LH. Gene expression profiles in childhood acute lymphoblastic leukemia identify prognostic roles for multidrug resistance-associated protein 2 (MRP2) and reduced folate carrier (RFC). Presented at the Annual Meeting of the American Association for Cancer Research, Washington, D.C., Apr. 2006. [abstract 4323]
62. Gamis AS, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Erdly L, McGavran, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arcecci R. Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial- Initial Report of the COG Trial A2971. Presented at the Annual Meeting of the American Society of Hematology, Orlando, FL., Dec. 2006. [abstract 15]
63. O'Brien M, Taub J, Stine K, Chang M, Ravindranath Y, Becton D, Dahl GV. Excessive cardiotoxicity despite excellent leukemia-free survival for pediatric patients with Down syndrome and acute myelogenous leukemia: Results from POG protocol 9421. Presented at the Annual Meeting of the American Society of Hematology, Orlando, FL., Dec. 2006. [abstract 559]
64. Larson A, Ge Y, LaFiura K, Devidas M, Linda SB, Taub JW, Matherly LH. Association of NOTCH1 mutations in pediatric T-cell acute lymphoblastic leukemia with treatment relapse and expression of genes relevant to chemotherapy response. Presented at the American Association for Cancer Research Annual Meeting April 2007.
65. Alcasabas P, del Rosario ML, Ravindranath Y, Goyette G, Haller A, Lesaca MY, Darga L, Ostrea E, Taub J, Everson R. 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphisms and the risk of acute lymphoblastic leukemia (ALL) in Filipino children. Presented at the 39th Annual Meeting of the International Society of Paediatric Oncology SIOP 2007, Mumbai, India, Sept. 2007. *Pediatric, Blood and Cancer* 49: abstract O.071, 2007.
66. Deng Y, Wang Y, Cherian C, Hou Z, Taub JW, Gangjee A, Matherly LH. A series of novel 6-substituted 2-amino-4-oxopyrrolo[2,3-d]pyrimidine antifolates specifically transported by folate receptors and targeting the de novo purine biosynthesis pathway. Presented at the American Association for Cancer Research Annual Meeting April 2008.
67. Chen Q, Gedman AL, Matherly LH, Taub JW. Analysis of clonal T-cell receptor gamma gene rearrangements, NOTCH1, FBW7 and PTEN mutations in paired pediatric T-cell acute lymphoblastic leukemia samples at diagnosis and relapse reveals evidence of relapse in new leukemic clones. Presented at the Annual Meeting of the American Society of Hematology, San Francisco, CA., Dec. 2008. [abstract 1488]
68. Xavier AC, Edwards H, Xie C, Dombkowski AA, Buck SA, Matherly LH, Ge Y, Taub JW. The role of short form GATA1 protein in Down syndrome biology and therapy. Presented at the Annual Meeting of the American Association for Cancer Research, Denver, CO. April 18-22 2009.

69. Gedman AL, Chen Q, Desmoulin SK, Christina Cherian, Meenakshi Devidas M, Stephen B. Linda SB, Ge Y, Taub JW, Matherly LH. The impact of NOTCH1 on PI3K-AKT signaling and dependence on the PTEN status in T-cell acute lymphoblastic leukemia. Presented at the Annual Meeting of the American Association for Cancer Research, Denver, CO. April 18-22, 2009.
70. Xie C, Edwards H, LoGrasso SB, Stout ML, Buck SA, Taub JW, Ge Y. Valproic acid synergistically enhances clofarabine cytotoxicity in pediatric acute myeloid leukemia. Presented at the Annual Meeting of the American Association for Cancer Research. Presented at the Annual Meeting of the American Association for Cancer Research, Denver, CO. April 18-22, 2009.
71. Xavier AC, Edwards H, Xie C, Dombkowski AA, Buck SA, Matherly LH, Ge Y, Taub JW. The role of short form GATA1 protein in Down syndrome biology and therapy. Presented at the Plenary Session of the Annual Meeting of the American Society of Pediatric Hematology/Oncology Annual Meeting. Plenary Session. Hilton San Diego Bayfront Hotel. April 23, 2009.
72. Rubnitz J, Inaba H, Dahl G, Bowman WP, Taub J, Pui CH, Stanley Pounds S, Lacayo NJ, Cao X, Ribeiro RC, Meshinchi S, Degar B, Airewele G, Mihaela Onciu M, Coustan-Smith E and Dario Campana D. Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial. Presented at the Annual Meeting of the American Society of Hematology, New Orleans, LA, Dec. 5-8, 2009.
73. Xie C, Edwards H, Polin L, Zhou H, Wang X, Yang S, LoGrasso SB, Buck SA, Stout ML, Rubnitz JE, Matherly LH, Taub JW, Yu Q, Ge Y. Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine: A Potential Means to Improve the Treatment of Pediatric Acute Myeloid Leukemia. Presented at the Annual Meeting of the American Society of Hematology, New Orleans, LA, Dec. 5-8, 2009.
74. Edwards H, Xie C, Dombkowski AA, Keller M, Stout ML, Buck SA, Matherly LH, Taub JW, Ge Y. Overexpression of GATA1 Confers Chemotherapy Resistance in Pediatric Acute Megakaryocytic Leukemia. Presented at the Annual Meeting of the American Society of Hematology, New Orleans, LA, Dec. 5-8, 2009.
75. O'Brien M, Dahl G, Pounds S, Lacayo NJ, Taub J, Chang M, Weinstein HJ, Ravindranath Y, Campana D, Pui CH, Rubnitz J. Acute megakaryoblastic leukemia (AMKL) in children without Down syndrome. Presented at the Annual Meeting of the American Society of Hematology, New Orleans, LA, Dec. 5-8, 2009.
76. Gedman AL, Dombkowski A, Ge Y, Taub JW, Matherly LH. Loss of NOTCH1 is associated with decreased expression of hsa-miR-125a-5p in T-cell acute lymphoblastic leukemia: Implications for using NOTCH1 inhibition in chemotherapy. Presented at the Annual Meeting of the American Association for Cancer Research, Washington, D.C., April 17-21, 2010.
77. Yankelevich M, Chkadua G, Taub JW, Budarin M, Poulik JM, Mentkevich G, Bhambhani K. Primary leptomeningeal melanoma in children: an attempt at immunotherapy. Presented at the 14th International Symposium on Pediatric Neuro-Oncology. Vienna, Austria. June 20-23, 2010.

78. Xu X, Xie C, Edwards H, Zhou H, Buck S, Matherly L, Taub J, Yubin Ge Y. Inhibition of Histone Deacetylases 1 and 6 Enhances Ara-C-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells. Presented at the Annual Meeting of the American Society of Hematology, Orlando, FL, Dec. 4-7, 2010.
79. Wang G, He J, Zhang A, Taub JW, Guo Y, Ge Y. Both Class I and Class II Histone Deacetylases Are Required for Proliferation and Survival of Human Pancreatic Cancer Cells. Presented at the Annual Meeting of the American Association for Cancer Research, Chicago, IL, March 31-April. 4, 2012.
80. Xie C, Edwards H, Drenberg C, Baker SD, Inaba H, Xu X Buck SA, Taub JW, Ge Y. Panobinostat Potentiates the Cytotoxic Effects of Ara-C and Daunorubicin on Acute Myeloid Leukemia Cells through Suppressing the DNA Damage Response. Presented at the Annual Meeting of the American Association for Cancer Research, Chicago, IL, March 31-April 4, 2012.
81. Hales E, Orr S, Larson Gedman A, Taub JW, Matherly LH. Mechanisms for cross-talk between Notch1 and AKT signaling in T-cell acute lymphoblastic leukemia. Presented at the Annual Meeting of the American Association for Cancer Research, Chicago, IL, March 31-April 4, 2012.
82. Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Berman JN, Meshinchi S, Taub JW, Gamis AS. Remission marrow blast percentage predicts relapse risk in children with myeloid leukemia associated with Down syndrome. Presented at the Annual Meeting of the American Society of Pediatric Hematology/Oncology, New Orleans, LA, May 2012.
83. Konski A, Hallock A, Snyder M, McSpadden E, Weigh A, Savasan S, Henry M, Cushing B, Maier J, Ravindranath Y, Bergman D, Taub JW. Normal Tissue Complication Probability Model for Lung Toxicity after Radiotherapy in Pediatric Patients with Hodgkins Lymphoma Receiving Bleomycin. Presented at the Annual SIOP meeting London, England. October 2012.
84. Penner LA, Harper FHWK, Peterson AM, Uphold HU, Taub J, Albrecht TL. Temperament, Personality, and Quality of Life in Pediatric Cancer Patients. Presented at the World Congress meeting of the International Psycho-Oncology Society in Brisbane, Australia November 13th – 15th 2012.
85. Penner LA, Kross E, Harper FHWK, Peterson AM, Uphold HU, Taub J, Albrecht TL. From A Distance: The Influence of Dispositions and Self-distanced Analyses on Affect Among Parents of Pediatric Cancer. Presented at the World Congress meeting of the International Psycho-Oncology Society in Brisbane, Australia November 13th – 15th 2012.
86. Cooper T, Alonzo T, Gerbing R, Perentesis J, Whitlock J, Taub JW, Horton T, Gamis A, Razzouk B. AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia. Presented at the Annual Meeting of the American Society of Hematology. Atlanta, GA December 2012.
87. K Mast, JW Taub, C Mosse, P Matthew, J Hitzler, T Alonzo, H Jones, AS Gamis, and D Head. Morphology of Myeloid Leukemia of Down Syndrome. Presented at the 2013 United States & Canadian Academy of Pathology Annual Meeting. Modern Pathology. 2013; 26,Supp 2:345A

88. Hales EC, Orr SM, Gedman AL, Taub JW, Matherly LH. Notch1 regulates AKT activation loop (T308) dephosphorylation through modulation of the PP2A phosphatase in PTEN-null T-cell acute lymphoblastic leukemia cells. Presented at the Annual meeting of the American Association for Cancer Research. April 2013.
89. Wang G, Edwards H, Caldwell JT, Buck SA, Qing WY, Taub JW, Ge Y, Wang Z. Synergistic antitumor interactions between panobinostat and conventional chemotherapy drugs in high-risk neuroblastoma. Presented at the 45th congress of the International Society of Paediatric Oncology (SIOP), Hong Kong, 25-28th September, 2013.
90. Karol SE, Coustan-Smith E, Cao X, Shurtleff SA, Raimondi SC, Choi JK, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D, Inaba H. Prognostic Factors for Children with Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status after Induction Therapy. Presented at the Annual Meeting of the American Society of Hematology. New Orleans, LA December 2013.
91. Caldwell JT, Buck SA, Ge Y, Taub JW. Targeting The Wee1 Kinase With MK-1775 For Treatment Of Acute Myeloid Leukemia In The Down Syndrome Population. Presented at the Annual Meeting of the American Society of Hematology. New Orleans, LA December 2013.
92. Xie C, Edwards H, Caldwell JT, Taub JW, Ge Y. At Clinically Achievable Concentrations Obatoclox (GX15-070) Potentiates the Cytotoxic Effect of Cytarabine on Acute Myeloid Leukemia Cells by Enhancing DNA Damage. Presented at the Annual Meeting of the American Society of Hematology. New Orleans, LA December 2013.
93. Harper FWK, Peterson AM, Uphold H, Taub JW, Phipps S, Albrecht TL, Penner LA. Parent religiosity/spirituality and parent responses to pediatric oncology treatment procedures. American Psychosocial Oncology Society Annual Meeting, Tampa, FL. (podium presentation), February 2014.
94. Penner L, Harper F, Peterson A, Trentacosta C, Taub J, Phipps S, Albrecht T. Reducing psychosocial difficulties among parents of pediatric cancer patients: The moderating effects of social support. American Psychosocial Oncology Society Annual Meeting, Tampa, FL. (podium presentation), February 2014.
95. Uphold H, Harper F, Peterson A, Fox J, Foster T, Taub JW, Albrecht TL, Penner LA. longitudinal look at basic needs of pediatric oncology patients, their families, and their psycho-social adjustment. American Psychosocial Oncology Society Annual Meeting, Tampa, FL, February 2014.
96. Peterson AM, Merolla D, Harper FWK, Hankin JR, Penner LA. The effect of social support on child and parent reactions to pediatric cancer treatment procedures. American Psychosocial Oncology Society Annual Meeting, Tampa, FL, February 2014.
97. Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Gerbing RB, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS. Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children's Oncology Group (COG) Phase III AAML0431 Trial. Oral Presentation at the Annual Meeting of the American Society of Hematology, San Francisco, CA December 2014.

98. Sorge CE, Costa LJ, Taub JW, Xavier AC. Incidence and Outcomes of Rare Pediatric Non-Hodgkin Lymphomas. Presented at the 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. Plenary Session – Best Oral Abstracts in Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Italy. Nov. 2015.
99. Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, Caldwell JT, Chu R, Wang Z, Lin H, Taub JW, Ge Y. Binding of released bim to mcl-1 is responsible for resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in acute myeloid leukemia cells. Presented at the Annual meeting of the American Society of Hematology Annual Meeting, Orlando, FL, Dec. 2015.
100. Zhao J, Niu X, Edwards H, Wang Y, Taub JW, Lin H, Ge Y. Inhibition of chk1 enhances cell death induced by the bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Presented at the Annual meeting of the American Society of Hematology Annual Meeting, Orlando, FL, Dec. 2015.
101. Xinyu Li, Jun Ma, Yongwei Su, Jianyun Zhao, Holly Edwards, Yue Wang, Jay Yang, Jeffrey W Taub, Hai Lin, Yubin Ge. Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo. Presented at the Annual meeting of the American Society of Hematology Annual Meeting, San Diego, CA, Dec. 2016.
102. Hutchins KK, Savasan S, Thomas R, Strathdee L, Taub JW. Clinical trial enrollment and follow-up visit rates among survivors of childhood cancer. Presented at the 2017 Cancer Survivorship Symposium (ASCO), San Diego, CA, Jan 27-28, 2017.
103. Su Y, Li X, Zhao J, Ma J, Liu S, Edwards H, Taub JW, Lin H, Ge Y. Targeting PI3K, mTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML Presented at the Annual meeting of the American Society of Hematology Annual Meeting, Atlanta, GA, Dec. 2017.
104. Su Y, Li X, Edwards H, Allen JE, Stogniew M, Prabhu VV, Taub JW, Lin H, Ge Y. ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells in Vitro and In Vivo. Presented at the Annual meeting of the American Society of Hematology Annual Meeting, Atlanta, GA, Dec. 2017.
105. Luedtk DA, Su Y, Edwards H, Lin H, Taub JW, Ge Y. Inhibition of XPO1 by KPT-330 (Selinexor) Enhances Cell Death Induced by the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia. Presented at the Annual meeting of the American Society of Hematology Annual Meeting, Atlanta, GA, Dec. 2017.
106. Brown AL, de Smith AJ, Michael E. Scheurer ME, Kallsen NA, Peyton SA, Davies GE, Ehli EA, Zwick ME, Winick N, Maloney K, Angiolillo AL, Schore R, Burke MM, Salzer WL, Heerema NA, Carroll AJ, Borowitz MJ, Wood BL, Carroll WL, Raetz EA, Feingold E, Sherman SL, Yang W, Devidas M, Walsh K, DeWan AT, Pombo-de-Oliveira MS, Taub JW, Sinnott D, Healy J, Birch JM, Barcellos LF, Hansen H, Smirnov I, Mullighan CG, Hunger SP, Pui CH, Loh M, Wiemels JL, Ma X, Metayer C, Mueller BA, Relling MV, Yang JJ, Lup PJ, Rabin KR. Genome-wide association study of acute lymphoblastic leukemia in children with Down syndrome. Presented at the Annual Meeting of the American Association for Cancer Research, Chicago, IL, April 2018.

107. Labuhn M, Perkins K, Papaemmanuil E, Garnett C, Matzk S, Amstislavskiy V, Metzner M, Alison Kennedy A, Scheer C, Yoshida K, Schwarzer A, Crispino JD, Jeffrey W. Taub JW, Mitchell J. Weiss MJ, Etsuro Ito E, Ogawa S, Reinhardt D, Marie-Laure Yaspo ML, Campbell PJ, Heckl D, Klusmann JH, Vyas P. Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome. Presented at the Annual meeting of the
108. Su Y, Li X, Edwards H, Polin L, Kushner J, Dzinic SH, Hege K, Fukuda Y, Schuetz JD, Allen JE, Stogniew M, Prabhu VV, Taub JW, Lin H, Ge Y. Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia. Presented at the Annual meeting of the American Society of Hematology Annual Meeting, San Diego, CA, Dec. 2018.
109. Luedtke DA, Su Y, Edwards H, Polin L, Kushner J, Dzinic SH, Lin H, Taub JW, Ge Y. Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia. Presented at the Annual meeting of the American Society of Hematology Annual Meeting, San Diego, CA, Dec. 2018.
110. Knight T, Qiao X, Edwards H, Lin H, Taub JW, Ge Y. Novel Therapy for FLT3-ITD Acute Myeloid Leukemia Utilizing the Combination of CUDC-907 and Gilteritinib. Presented at the Annual meeting of the American Society of Hematology Annual Meeting, San Diego, CA, Dec. 2018.
111. Hitzler J, Berman J, Gerbing R, Beckman A, Hirsch B, Raimondi S, Druley T, Loken M, Brodersen L, Chisholm K, Viola S, Taub J, Gamis A, Alonzo T, Kolb EA. High-dose Cytarabine Remains Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction. Presented at the American Society of Hematology Annual Meeting, Orlando, FL, Dec. 2019.
112. Knight T, Qiao X, Ma J, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Lin H, Wang Y, Taub JW, Ge Y. The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML. Presented at the American Society of Hematology Annual Meeting, Orlando, FL, Dec. 2019.
113. Gadgeel M, AlQanber B, Buck S, Taub JW, Yaddanapudi Ravindranath Y, Savaşan S. Aberrant mature myeloid cell CD56 expression in down syndrome is not linked to leukomogenesis. Annual meeting of the American Society of Pediatric Hematology Oncology, May 2020.

Invited Lectures/Presentations:

International/National

1. Taub JW. Grand Rounds, Department of Pathology, University of California-Davis, Sacramento, CA, April 5, 2000, "Down Syndrome, Leukemia, and Cystathionine- β -synthase."
2. Taub JW. Chromosome 21 and Leukemia. Blood Club, Annual Meeting of the Society for Pediatric Research, Boston, MA, May 13, 2000.
3. Taub JW. Down Syndrome, Leukemia and Cystathionine- β -synthase. At the Myeloid Mini-Symposium, Nov. 3, 2000. Children's Oncology Group (COG) Fall Meeting, Phoenix, AZ.

4. Taub JW. Down Syndrome, Leukemia and Chromosome 21. Pediatric Grand Rounds, M.D. Anderson Cancer Center, Houston, TX, June 4, 2001.
5. Taub JW. Down Syndrome, leukemia and chromosome 21. Hematology/Oncology Grand Rounds, St. Jude Children's Research Hospital, Memphis, TN, May 16, 2002.
6. Taub JW. Down Syndrome, leukemia and chromosome 21. Pediatric Grand Rounds, University of Chicago, Oct. 9, 2003.
7. Taub JW. Retinoblastoma. Pediatric Lecture Series, University of Chicago, Oct. 9, 2003.
8. Taub JW. Down Syndrome, Drug Metabolism and Chromosome 21. Down Syndrome and Leukemia Symposium. Nov. 6, 2003. Children's Oncology Group (COG) Fall Meeting, Dallas, TX.
9. Taub JW. GATA1, Chromosome 21 and Leukemia Therapy. 3rd Annual Institute of Child Health/Great Ormond Street Hospital Pediatric Haematology/Oncology Symposium, London, England, March 23-24, 2006.
10. Taub JW. Lessons learned from Down syndrome and AMkL. Advancing the Outcome of Acute Myeloid Leukemia through the Integration of Clinical and Biological Investigation. St. Jude Children's Research Hospital, Sept. 27-29, 2006.
11. Taub JW. Lessons learned from Down syndrome and leukemia. Pediatric Hematology/Oncology Grand Rounds. Texas Children's Hospital, Dec. 21, 2006
12. Taub JW: Down Syndrome, Leukemia and Chromosome 21. Pediatric and Adult Hematology Conference, University of Michigan Medical Center, March 28, 2007.
13. Taub JW. Down Syndrome and Leukemia: A Model of Leukemogenesis and Cure. Pediatric Grand Rounds, University of Minnesota, August 1, 2007.
14. Taub JW. Down Syndrome, Leukemia and Chromosome 21. Pediatric Grand Rounds, Uniformed Services University, Bethesda, MD, August 23, 2007.
15. Taub JW. Chemotherapy Pharmacology of Down Syndrome Children with Leukemia. Annual Meeting of the American Society of Pediatric Hematology Oncology. San Diego, CA, April 23, 2009.
16. Taub JW. The Unique biology of Leukemia and Down Syndrome. City of Hope National Medical Center. Duarte, CA, Oct. 20, 2010.
17. Taub JW. Overview of Acute Leukemias in Down Syndrome Children. De Vos Children's Hospital, Grand Rapids, MI, Nov. 18, 2010.
18. Taub JW. The Unique Clinical and Biological Features of Leukemias in Children with Down Syndrome. Linda Crnic Institute for Down Syndrome, University of Colorado, Aurora, CO, March 7, 2012.
19. Taub JW. Update on Acute Myeloid Leukemia. Children's Hematology Alliance of Michigan (CHAMI) Educational Symposium. Ann Arbor, MI, May 17, 2013.

20. Taub JW. Acute Myeloid Leukemia in Down Syndrome-Lessons and Opportunities. 46th Annual Meeting of the International Society of Pediatric Oncology. Toronto, Canada, October 23, 2014.
21. Taub JW. Acute Myeloid Leukemia in Down Syndrome. American Society of Pediatric Hematology/Oncology (ASPHO) Webinar. September 22, 2016.
22. Taub JW. Down Syndrome and Acute Myeloid Leukemia. Pediatric Oncology Group of Ontario (POGO) 2016 Multi-disciplinary Symposium on Childhood Cancer. Nov. 4-5, 2016, Toronto, Ontario.
23. Taub JW. Childhood Leukemias. Pediatric Grand Rounds. Children's of Alabama, Birmingham, Alabama, September 7, 2017.
24. Taub JW. Leukemia in Children with Down Syndrome: Treading Carefully with Clinical Trials. National Institutes of Health: Clinical Trials in Down Syndrome for Co-occurring Conditions Across the Lifespan Workshop. May 7, 2020.

Local/Regional:

1. Taub JW, Matherly LH, Buck S, Stout M, Ravindranath Y. Enhanced formation of cytosine arabinoside triphosphate (ara-CTP) in Down Syndrome cells: a contributing factor to the superior disease-free survival rate of Down Syndrome children with acute myeloid leukemia. Presented at the American Cancer Society (Michigan Division) Fifth Annual Research conference, held Friday, 11/18/94, Hutzel Hospital, Detroit Medical Center, Detroit MI.
2. Taub JW (Keynote Speaker). Advances in the cure of childhood cancer. Children's Hospital of Michigan. Childhood Cancer Survivor Symposium. Children's Hospital of Michigan, 06/08/96.
3. Taub JW. "What's New in Cancer Therapy." Metropolitan Detroit Coalition for Cancer Survivorship conference. Farmington Hills MI. 03/08/97.
4. Taub JW. "Research and Informed Consent". Presented at Grand Rounds, April 25, 1997, Children's Hospital of Michigan, Detroit MI.
5. Wozniak MM, Ellis DA, Taub JW. Neuropsychological abnormalities in childhood acute lymphoblastic leukemia (ALL) survivors treated with systemic methotrexate with craniospinal irradiation. Children's Hospital of Michigan, Fellowship Research Presentation, 05/13/97, CHM, Detroit MI.
6. Taub JW, Ravindranath Y, Ekizian R, Wong SC, Buck SA, Simpson P, Matherly LH. Elevated dihydrofolate reductase levels are a common finding in African American children with B-precursor acute lymphoblastic leukemia at diagnosis: a potential mechanism leading to treatment failure. Presented at 40th Annual Children's Hospital of Michigan Clinic Days, 05/21/97, CHM, Detroit MI.
7. Taub JW. Late effects of cancer therapy. Quality of life issues for cancer patients and their families. Children's Leukemia Foundation of Michigan, Dearborn, MI, 04/22/98.
8. Taub JW. Chromosome 21 and Leukemia. Presented at Grand Rounds, July 17, 1998, at Children's Hospital of Michigan, Detroit MI.
9. Taub JW (Invited Speaker). Michigan March for Cancer. Lansing, MI, Sept. 26, 1998.

10. Taub JW. Chromosome 21 and Leukemia. Grand Rounds, Oct. 14, 1998. Karmanos Cancer Institute, Harper Hospital, Detroit, MI.
11. Taub JW. Chromosome 21 and Leukemia. Pediatric Grand Rounds, Dec. 1, 1998, William Beaumont Hospital, Royal Oak, MI.
12. Taub JW. "Meeting the Needs of Cancer Survivors and Their Families". Metropolitan Detroit Coalition for Cancer Survivorship Conference, Southfield, MI. March 13, 1999.
13. Taub JW. Support issues in cancer treatment. Men's Support Club, Gilda's Club, Royal Oak, MI, Oct. 5, 1999.
14. Taub JW. Advances in Childhood Cancer. Gilda's Club, Royal Oak, MI, Jan. 17, 2001.
15. Taub JW. Chromosome 21 and Leukemia. Pediatric Blood Club of Michigan, Novi, MI, May 24, 2001.
16. Taub JW. Childhood Leukemia. Grand Rounds, Children's Hospital of Michigan, Detroit, MI, July 13, 2001.
17. Taub JW. Down Syndrome, chromosome 21 and leukemia chemotherapy. Dept. of Pharmacology, Wayne State University School of Medicine, Nov. 9, 2001.
18. Taub JW. What Causes Childhood Leukemia? Grand Rounds, Children's Hospital of Michigan, Detroit, MI, Dec. 5, 2003
19. Taub JW. Pathogenesis of Leukemia-When Does it Begin? Michigan Society of Hematology/Oncology 7th Annual Review of the American Society of Hematology Meeting, Dearborn, MI., Jan. 24, 2004.
20. Taub JW. The role of folates in both the etiology and treatment of childhood cancers. Department of Food and Nutrition Science, Wayne State University, Feb. 10, 2004.
21. Taub JW. Pediatric Blood Cancers. 2004 Annual Great Lakes Blood Cancer Conference, Sept. 18, 2004.
22. Taub JW. Pediatric Blood Cancers. 2005 Great Lakes Blood Cancer Conference, Oct. 8, 2005.
23. Taub JW. Childhood Cancer. Optimist Club of Shelby Township, Michigan, Oct. 23, 2006.
24. Taub JW. What Causes Childhood Leukemia? Pediatric Grand Rounds, William Beaumont Hospital, Royal Oak, Michigan, June 19, 2007.
25. Taub JW. Childhood Cancer: Is There a Price for a Cure? Gilda's Club, Royal Oak, Michigan, Sept. 19, 2007.
26. Taub, JW. Finding Clues to Understanding the Biology of Leukemia: In the Womb and on Chromosome 21. Karmanos Cancer Institute Research Retreat Apr. 4, 2008.

27. Taub JW. Down Syndrome and Leukemia: A Model of Leukemogenesis and Cure. William Beaumont Hospital 17th Annual Symposium on Molecular Pathology. Clinical Applications of Genomic Medicine. Sept. 10, 2008.
28. Chen Q, Fassinger N, Thomas R, Ge Y, Matherly LH, Taub JW. Altered Folate Metabolism may be Linked to the Development of Acute Lymphoblastic Leukemia (ALL) in African American Children. Presented at the 8th Annual Research Day-Children's Hospital of Michigan/Wayne State University and the Department of Pediatrics and Human Development/Michigan State University, Detroit, Michigan March 27, 2009.
29. Xavier AC, Edwards H, Xie C, Dombkowski AA, Buck SA, Matherly LH, Ge Y, Taub JW. The role of short form GATA1 protein in Down syndrome leukemogenesis and therapy. Presented at the 8th Annual Research Day-Children's Hospital of Michigan/Wayne State University and the Department of Pediatrics and Human Development/Michigan State University, Detroit, Michigan March 27, 2009.
30. Taub JW. Childhood Cancer-An Update. Pediatric Grand Rounds. Huron Valley Sinai Hospital. May 20, 2009.
31. Taub JW. Principles of Cancer Chemotherapy. ENT Journal Club-Detroit Medical Center. Children's Hospital of Michigan. June 16, 2009.
32. Taub JW. Childhood Cancer-An Update. Detroit Pediatric Society. Birmingham, Michigan. September 9, 2009.
33. Taub JW. Childhood Cancer in 2009- An Overview. CME Lecture Series in Pediatric Medicine. Birmingham, Michigan. November 14, 2009.
34. Taub JW. The Prenatal Origin of Childhood Leukemia. Grand Rounds, Children's Hospital of Michigan, December 18, 2009.
35. Taub JW. Differences in Etiology of Acute Lymphoblastic Leukemia Between Caucasian and African American Children. The Gerber Foundation, Grand Rapids, Michigan, May 20, 2010.
36. Taub JW. Review of common oncologic disorders in children. Pediatric Anesthesia Lecture Series. Children's Hospital of Michigan, November 10, 2010.
37. Taub JW. The Role of Genetics in Childhood Leukemias. Karmanos Cancer Institute Clinical Genetics Conference. Sept. 26, 2011
38. Taub JW. What Fish Can Teach Us About Leukemia. Herrick Foundation Grant Program. Karmanos Cancer Institute Grand Rounds. Oct. 13, 2011.
39. Taub JW. Childhood Cancer in 2011: An Overview. Pediatric Grand Rounds. St. Joseph's Hospital, Ann Arbor, MI. Nov. 3, 2011.
40. Taub JW. Pediatric Oncology in 2012-An Update. Pediatric Surgery Grand Rounds, Children's Hospital of Michigan, Feb 15, 2012.
41. Taub JW. Pediatric Leukemias: Causes and Cures. Wayne State University Otolaryngology Research Group, March 18, 2013.

42. Taub JW. Childhood Cancer 2013. Causes, Catching it Early, Cures. CME Lecture Series in Pediatric Medicine. Children's Hospital of Michigan. April 20, 2013.
43. Taub JW. Childhood Cancer Update 2013. CME lecture. Bloomfield Hills, MI. November 13, 2013.
44. Taub JW. Childhood Cancer Update. Children's Hospital of Michigan Pediatric Grand Rounds. January 31, 2014
45. Taub JW. Pediatric Oncology in 2014- Progress & Hope. Gilda's Club, Royal Oak, Michigan July 30, 2014.
46. Taub JW. ABCs of the CBC. Pediatric Grand Rounds, Huron Valley Sinai Hospital, November 19, 2014.
47. Taub JW. Down syndrome: A Model of Curing Acute Myeloid Leukemia. Karmanos Cancer Institute Molecular Therapeutics Program Annual Research Symposium, June 17, 2015.
48. Taub JW. Acute Myeloid Leukemia-how can we fix it? MED TALKS. Children's Hospital of Michigan Foundation MED TALKS, November 4, 2015.
49. Taub JW. Translational Research-How Your Patients Can Inspire Research Projects. Children's Hospital of Michigan Fellow's Research Lecture. November 16, 2016.
50. Taub JW. Childhood Cancer Update 2017. Pediatric Grand Rounds. Macomb McLaren Hospital. February 8, 2017.
51. Taub JW. Anemia. Huron Valley Sinai Hospital. March 22, 2017.
52. Hutchins KK, Savasan S, Thomas R, Strathdee L, Taub JW. Clinical trial enrollment and follow-up visit rates among survivors of childhood cancer. Presented at the 16th Annual Pediatric Research Day. Wayne State University, March 29, 2017.
53. Jamerino J, Hutchins KK, Henning W, Taub JW. Survivors of childhood cancer and their awareness of increased chronic health conditions: Survey results from the Children's Hospital of Michigan's "Celebration of Life". Presented at the 16th Annual Pediatric Research Day. Wayne State University, March 29, 2017.
54. Taub JW. Childhood Cancer Update 2018. Presented at the 40th Annual meeting of the national meeting of the Arab American Medical Association. Detroit, MI, September 2, 2018.
55. Taub JW. Translational Research-How Your Patients Can Inspire Research Projects. 7th Annual MD/PHD Wayne State University School of Medicine retreat. September 6, 2019.
56. Taub JW. Clues to Diagnosing Pediatric Cancers: Pearls and Pitfalls. Chat with a Pediatric Specialist. Children's Hospital of Michigan. May 15, 2020.
57. Taub JW. Translational Research-How Your Patients Can Inspire Research Projects. Children's Hospital of Michigan Fellow Research Lecture. August 12, 2020.
58. Taub, JW. Curing cancer with dirt, Great Lakes shipwrecks and the flowers in your garden. Children's Hospital of Michigan Pediatric Hematology/Oncology Lecture. October 1, 2020.

59. Taub JW. Clues to Diagnosing Pediatric Cancers: Pearls and Pitfalls. Pediatric Grand Rounds. St. Joseph's Hospital-Ann Arbor. March 18, 2021.